<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Cubist Pharmaceuticals Inc.</title>
	<atom:link href="http://www.stockbloghub.com/tag/cubist-pharmaceuticals-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Mon, 20 May 2013 16:48:42 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.5.1</generator>
		<item>
		<title>(ENDP) Endo Health Solutions Sees FDA Setback on Opana ER</title>
		<link>http://www.stockbloghub.com/2013/05/15/endp-endo-health-solutions-sees-fda-setback-on-opana-er/136028</link>
		<comments>http://www.stockbloghub.com/2013/05/15/endp-endo-health-solutions-sees-fda-setback-on-opana-er/136028#comments</comments>
		<pubDate>Wed, 15 May 2013 16:47:11 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Canadian Pacific Railway Limited]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[CP]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Endo Pharmaceuticals Holdings Inc]]></category>
		<category><![CDATA[ENDP]]></category>
		<category><![CDATA[Lannett Company Inc]]></category>
		<category><![CDATA[LCI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=136028</guid>
		<description><![CDATA[Endo Health Solutions Inc. (ENDP) recently suffered a setback with the US Food and Drug Administration (FDA) turning down its request to prevent the entry of generic versions of the company’s painkiller Opana ER. We remind investors that Endo had filed a Citizen Petition (CP) with the FDA in 2012. Through the CP, the company had sought a formal determination whether the original version (non-tamper resistant) of the drug was voluntarily removed from the market in 2012 for safety reasons (involving its abuse). We remind investors that the new formulation of Opana ER, which is designed to resist attempts of crushing, breaking, pulverizing or making a powder of the product, was approved by the FDA in 2011. Through the CP, Endo had requested the FDA not to clear non-tamper resistant ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2013/05/15/endp-endo-health-solutions-sees-fda-setback-on-opana-er/136028/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(FRX) Forest Laboratories Sees Positive Data on Combo Drug</title>
		<link>http://www.stockbloghub.com/2013/05/07/frx-forest-laboratories-sees-positive-data-on-combo-drug/135629</link>
		<comments>http://www.stockbloghub.com/2013/05/07/frx-forest-laboratories-sees-positive-data-on-combo-drug/135629#comments</comments>
		<pubDate>Tue, 07 May 2013 21:22:29 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Catalyst Pharmaceutical Partners Inc]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[CPRX]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=135629</guid>
		<description><![CDATA[Forest Laboratories, Inc. (FRX) and Almirall, S.A. recently announced positive top-line data on their chronic obstructive pulmonary disease (COPD) fixed dose combination candidate, aclidinium bromide (LAMA) and formoterol fumarate (LABA). Two fixed dose combinations – aclidinium/formoterol (400/6mcg and 400/12mcg given twice a day) – were evaluated in the six month pivotal phase III study named AUGMENT COPD. Results showed that both combinations achieved a statistically significant improvement in the co-primary endpoints compared to placebo. Forest Labs said that both doses were found to be well-tolerated with common adverse events including cough, headache, urinary tract infection and back pain among others. Aclidinium/formoterol was administered using Almirall’s inhaler Genuair (US trade name: Pressair) The results presented from this study were consistent with results presented last month from another pivotal phase III study ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2013/05/07/frx-forest-laboratories-sees-positive-data-on-combo-drug/135629/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CBST) Cubist Pharmaceuticals Sees Encouraging News From FDA</title>
		<link>http://www.stockbloghub.com/2013/03/05/cbst-encouraging-news-for-cubist-pharmaceuticals-analyst-blog/129743</link>
		<comments>http://www.stockbloghub.com/2013/03/05/cbst-encouraging-news-for-cubist-pharmaceuticals-analyst-blog/129743#comments</comments>
		<pubDate>Tue, 05 Mar 2013 17:06:35 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Array BioPharma Inc.]]></category>
		<category><![CDATA[ARRY]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[GAIN]]></category>
		<category><![CDATA[Gladstone Investment Corporation]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[Optimer Pharmaceuticals Inc]]></category>
		<category><![CDATA[OPTR]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=129743</guid>
		<description><![CDATA[Recently, Cubist Pharmaceuticals Inc. (CBST) received some encouraging news when the US Food and Drug Administration (FDA) designated its antibiotic candidate CXA-201 (ceftolozane/tazobactam) as a qualified infectious disease product (QIDP), under the Generating Antibiotic Incentives Now (GAIN) Act. The designation was granted for the hospital-acquired bacterial pneumonia (HABP)/ventilator-associated bacterial pneumonia (VABP) and complicated urinary tract infections (cUTI) indications. CXA-201 is undergoing phase III studies for the cUTI indication. The company intends to evaluate the candidate in a phase III study for treating patients suffering from VABP. The study is expected to commence in mid-2013. With the FDA granting CXA-201 QIDP status for the above indications, the antibiotic qualifies for multiple benefits including a 5-year extension of Hatch-Waxman exclusivity (on approval) and priority review. We note that the GAIN act was ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2013/03/05/cbst-encouraging-news-for-cubist-pharmaceuticals-analyst-blog/129743/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AAPL) Fourth Quarter 2012 Earnings Season Gets Into High Gear &#8211; Earnings Preview</title>
		<link>http://www.stockbloghub.com/2013/01/20/aapl-fourth-quarter-2012-earnings-season-gets-into-high-gear-earnings-preview/126708</link>
		<comments>http://www.stockbloghub.com/2013/01/20/aapl-fourth-quarter-2012-earnings-season-gets-into-high-gear-earnings-preview/126708#comments</comments>
		<pubDate>Sun, 20 Jan 2013 17:56:37 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Personal Computers]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[3M Company]]></category>
		<category><![CDATA[8x8 Inc]]></category>
		<category><![CDATA[AAPL]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACAT]]></category>
		<category><![CDATA[Advanced Micro Devices Inc.]]></category>
		<category><![CDATA[AEP Industries Inc.]]></category>
		<category><![CDATA[AEPI]]></category>
		<category><![CDATA[AF]]></category>
		<category><![CDATA[Air Products & Chemicals Inc.]]></category>
		<category><![CDATA[Airgas Inc.]]></category>
		<category><![CDATA[Alaska Air Group Inc.]]></category>
		<category><![CDATA[ALB]]></category>
		<category><![CDATA[Albemarle Corporation]]></category>
		<category><![CDATA[ALK]]></category>
		<category><![CDATA[Allegheny Technologies Inc]]></category>
		<category><![CDATA[Altera Corporation]]></category>
		<category><![CDATA[ALTR]]></category>
		<category><![CDATA[AMD]]></category>
		<category><![CDATA[AME]]></category>
		<category><![CDATA[American River Bankshares]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[Ametek Inc.]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[AMRB]]></category>
		<category><![CDATA[AMTD]]></category>
		<category><![CDATA[Anaren Inc.]]></category>
		<category><![CDATA[ANEN]]></category>
		<category><![CDATA[AO Smith Corporation]]></category>
		<category><![CDATA[AOS]]></category>
		<category><![CDATA[APD]]></category>
		<category><![CDATA[Apple Inc.]]></category>
		<category><![CDATA[Arctic Cat Inc]]></category>
		<category><![CDATA[ARG]]></category>
		<category><![CDATA[Astoria Financial Corporation]]></category>
		<category><![CDATA[AT&T Inc.]]></category>
		<category><![CDATA[ATI]]></category>
		<category><![CDATA[Avnet Inc.]]></category>
		<category><![CDATA[AVT]]></category>
		<category><![CDATA[AVX]]></category>
		<category><![CDATA[AVX Corporation]]></category>
		<category><![CDATA[Baker Hughes Inc.]]></category>
		<category><![CDATA[BancorpSouth Inc.]]></category>
		<category><![CDATA[Bank of Marin Bancorp]]></category>
		<category><![CDATA[Banner Corporation]]></category>
		<category><![CDATA[BANR]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International Inc]]></category>
		<category><![CDATA[BC]]></category>
		<category><![CDATA[BGG]]></category>
		<category><![CDATA[BHI]]></category>
		<category><![CDATA[BMRC]]></category>
		<category><![CDATA[BMTC]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[BPOP]]></category>
		<category><![CDATA[Briggs & Stratton Corporation]]></category>
		<category><![CDATA[Brinker International Inc.]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Brunswick Corporation]]></category>
		<category><![CDATA[Bryn Mawr Bank Corporation]]></category>
		<category><![CDATA[BXS]]></category>
		<category><![CDATA[CA]]></category>
		<category><![CDATA[CA Inc.]]></category>
		<category><![CDATA[Cabot Microelectronics Corporation]]></category>
		<category><![CDATA[Canadian National Railway Company]]></category>
		<category><![CDATA[Cathay General Bancorp]]></category>
		<category><![CDATA[CATY]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[CBU]]></category>
		<category><![CDATA[CCI]]></category>
		<category><![CDATA[CCMP]]></category>
		<category><![CDATA[Celestica Inc.]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[Check Point Software Technologies Limited]]></category>
		<category><![CDATA[CHKP]]></category>
		<category><![CDATA[Cirrus Logic Inc.]]></category>
		<category><![CDATA[Citizens Republic Bancorp Inc]]></category>
		<category><![CDATA[City National Corporation]]></category>
		<category><![CDATA[CLP]]></category>
		<category><![CDATA[CLS]]></category>
		<category><![CDATA[CMCO]]></category>
		<category><![CDATA[CNI]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[Coach Inc.]]></category>
		<category><![CDATA[CoBiz Financial Inc]]></category>
		<category><![CDATA[COBZ]]></category>
		<category><![CDATA[COH]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[Coherent Inc]]></category>
		<category><![CDATA[COHR]]></category>
		<category><![CDATA[COLB]]></category>
		<category><![CDATA[Colonial Properties Trust]]></category>
		<category><![CDATA[Columbia Banking System Inc]]></category>
		<category><![CDATA[Columbus Mckinnon Corporation]]></category>
		<category><![CDATA[Community Bank System Inc]]></category>
		<category><![CDATA[Compuware Corporation]]></category>
		<category><![CDATA[Consolidated Edison Inc.]]></category>
		<category><![CDATA[Courier Corporation]]></category>
		<category><![CDATA[COV]]></category>
		<category><![CDATA[Covance Inc.]]></category>
		<category><![CDATA[Covidien plc]]></category>
		<category><![CDATA[CPWR]]></category>
		<category><![CDATA[CRBC]]></category>
		<category><![CDATA[CREE]]></category>
		<category><![CDATA[Cree Inc.]]></category>
		<category><![CDATA[Crown Castle International Corporation]]></category>
		<category><![CDATA[CRRC]]></category>
		<category><![CDATA[CRUS]]></category>
		<category><![CDATA[CSX]]></category>
		<category><![CDATA[CSX Corporation]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[CVD]]></category>
		<category><![CDATA[CY]]></category>
		<category><![CDATA[CYN]]></category>
		<category><![CDATA[Cypress Semiconductor Corporation]]></category>
		<category><![CDATA[DAL]]></category>
		<category><![CDATA[DCOM]]></category>
		<category><![CDATA[DD]]></category>
		<category><![CDATA[Delta Air Lines Inc.]]></category>
		<category><![CDATA[Deluxe Corporation]]></category>
		<category><![CDATA[DGII]]></category>
		<category><![CDATA[DGX]]></category>
		<category><![CDATA[Digi International Inc.]]></category>
		<category><![CDATA[Dime Community Bancshares Inc]]></category>
		<category><![CDATA[DLLR]]></category>
		<category><![CDATA[DLX]]></category>
		<category><![CDATA[Dollar Financial Corporation]]></category>
		<category><![CDATA[DOV]]></category>
		<category><![CDATA[Dover Corporation]]></category>
		<category><![CDATA[E*TRADE Financial Corporation]]></category>
		<category><![CDATA[Eagle Bancorp Inc]]></category>
		<category><![CDATA[East West Bancorp Inc]]></category>
		<category><![CDATA[EAT]]></category>
		<category><![CDATA[ED]]></category>
		<category><![CDATA[EFII]]></category>
		<category><![CDATA[EGBN]]></category>
		<category><![CDATA[EGHT]]></category>
		<category><![CDATA[EGN]]></category>
		<category><![CDATA[EI DuPont de Nemours & Company]]></category>
		<category><![CDATA[Electronics for Imaging Inc.]]></category>
		<category><![CDATA[Energen Corporation]]></category>
		<category><![CDATA[EQT]]></category>
		<category><![CDATA[EQT Corporation]]></category>
		<category><![CDATA[ESI]]></category>
		<category><![CDATA[ETFC]]></category>
		<category><![CDATA[ETH]]></category>
		<category><![CDATA[Ethan Allen Interiors Inc.]]></category>
		<category><![CDATA[EWBC]]></category>
		<category><![CDATA[EXAR]]></category>
		<category><![CDATA[Exar Corporation]]></category>
		<category><![CDATA[EZCORP Inc.]]></category>
		<category><![CDATA[EZPW]]></category>
		<category><![CDATA[F.N.B. Corporation]]></category>
		<category><![CDATA[F5 Networks Inc.]]></category>
		<category><![CDATA[Fairchild Semiconductor International Inc]]></category>
		<category><![CDATA[FBC]]></category>
		<category><![CDATA[FCFS]]></category>
		<category><![CDATA[FCS]]></category>
		<category><![CDATA[FCX]]></category>
		<category><![CDATA[Federated Investors Inc]]></category>
		<category><![CDATA[FFCH]]></category>
		<category><![CDATA[FFIV]]></category>
		<category><![CDATA[FII]]></category>
		<category><![CDATA[First Cash Financial Services Inc]]></category>
		<category><![CDATA[First Financial Holdings Inc]]></category>
		<category><![CDATA[First Merchants Corporation]]></category>
		<category><![CDATA[First Midwest Bancorp Inc]]></category>
		<category><![CDATA[FirstMerit Corporation]]></category>
		<category><![CDATA[Flagstar Bancorp Inc]]></category>
		<category><![CDATA[FLEX]]></category>
		<category><![CDATA[Flextronics International Limited]]></category>
		<category><![CDATA[FMBI]]></category>
		<category><![CDATA[FMER]]></category>
		<category><![CDATA[FNB]]></category>
		<category><![CDATA[Freeport-McMoRan Copper & Gold Inc]]></category>
		<category><![CDATA[FRME]]></category>
		<category><![CDATA[GATX Corporation]]></category>
		<category><![CDATA[GBCI]]></category>
		<category><![CDATA[GD]]></category>
		<category><![CDATA[General Dynamics Corporation]]></category>
		<category><![CDATA[Glacier Bancorp Inc]]></category>
		<category><![CDATA[GMT]]></category>
		<category><![CDATA[GOOG]]></category>
		<category><![CDATA[Google Inc.]]></category>
		<category><![CDATA[GWW]]></category>
		<category><![CDATA[HAFC]]></category>
		<category><![CDATA[HAL]]></category>
		<category><![CDATA[Halliburton Company]]></category>
		<category><![CDATA[Hancock Holding Company]]></category>
		<category><![CDATA[Hanmi Financial Corporation]]></category>
		<category><![CDATA[HBHC]]></category>
		<category><![CDATA[HEOP]]></category>
		<category><![CDATA[Heritage Oaks Bancorp]]></category>
		<category><![CDATA[Hexcel Corporation]]></category>
		<category><![CDATA[Hill-rom Holdings Inc]]></category>
		<category><![CDATA[HON]]></category>
		<category><![CDATA[Honeywell International Inc.]]></category>
		<category><![CDATA[HRC]]></category>
		<category><![CDATA[HUBB]]></category>
		<category><![CDATA[Hubbell Inc B Shares]]></category>
		<category><![CDATA[HXL]]></category>
		<category><![CDATA[IberiaBank Corporation]]></category>
		<category><![CDATA[IBKC]]></category>
		<category><![CDATA[IBM]]></category>
		<category><![CDATA[IGT]]></category>
		<category><![CDATA[II-VI Inc]]></category>
		<category><![CDATA[IIVI]]></category>
		<category><![CDATA[IMGN]]></category>
		<category><![CDATA[Immunogen Inc]]></category>
		<category><![CDATA[INDB]]></category>
		<category><![CDATA[Independent Bank Corporation]]></category>
		<category><![CDATA[INFA]]></category>
		<category><![CDATA[Informatica Corporation]]></category>
		<category><![CDATA[INTC]]></category>
		<category><![CDATA[Intel Corporation]]></category>
		<category><![CDATA[International Business Machines Corporation]]></category>
		<category><![CDATA[International Game Technology]]></category>
		<category><![CDATA[International Speedway Corporation]]></category>
		<category><![CDATA[Intuitive Surgical Inc]]></category>
		<category><![CDATA[Invesco Limited]]></category>
		<category><![CDATA[ISCA]]></category>
		<category><![CDATA[ISRG]]></category>
		<category><![CDATA[Iteris Inc]]></category>
		<category><![CDATA[ITI]]></category>
		<category><![CDATA[ITT Educational Services Inc.]]></category>
		<category><![CDATA[IVZ]]></category>
		<category><![CDATA[Jacobs Engineering Group Inc.]]></category>
		<category><![CDATA[Janus Capital Group Inc.]]></category>
		<category><![CDATA[JB Hunt Transport Services Inc]]></category>
		<category><![CDATA[JBHT]]></category>
		<category><![CDATA[JEC]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[JNPR]]></category>
		<category><![CDATA[JNS]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Juniper Networks Inc.]]></category>
		<category><![CDATA[Kansas City Southern]]></category>
		<category><![CDATA[Kennametal Inc.]]></category>
		<category><![CDATA[KEY]]></category>
		<category><![CDATA[Key Technology Inc]]></category>
		<category><![CDATA[KeyCorp]]></category>
		<category><![CDATA[Kimberly-Clark Corporation]]></category>
		<category><![CDATA[KLA-Tencor Corporation]]></category>
		<category><![CDATA[KLAC]]></category>
		<category><![CDATA[KMB]]></category>
		<category><![CDATA[KMT]]></category>
		<category><![CDATA[KSU]]></category>
		<category><![CDATA[KTEC]]></category>
		<category><![CDATA[Lam Research Corporation]]></category>
		<category><![CDATA[Lattice Semiconductor Corporation]]></category>
		<category><![CDATA[LCC]]></category>
		<category><![CDATA[LG Display Company Limited]]></category>
		<category><![CDATA[LMT]]></category>
		<category><![CDATA[Lockheed Martin Corporation]]></category>
		<category><![CDATA[LOGI]]></category>
		<category><![CDATA[Logitech International SA]]></category>
		<category><![CDATA[LPL]]></category>
		<category><![CDATA[LRCX]]></category>
		<category><![CDATA[LSCC]]></category>
		<category><![CDATA[LSI]]></category>
		<category><![CDATA[LSI Corporation]]></category>
		<category><![CDATA[LSI Industries Inc.]]></category>
		<category><![CDATA[LUV]]></category>
		<category><![CDATA[LYTS]]></category>
		<category><![CDATA[Marine Products Corporation]]></category>
		<category><![CDATA[Marten Transport Limited]]></category>
		<category><![CDATA[Maxim Integrated Products Inc]]></category>
		<category><![CDATA[MCBI]]></category>
		<category><![CDATA[McCormick & Company Inc]]></category>
		<category><![CDATA[MCD]]></category>
		<category><![CDATA[McDonald's Corporation]]></category>
		<category><![CDATA[MCRS]]></category>
		<category><![CDATA[MDP]]></category>
		<category><![CDATA[Mellanox Technologies Limited]]></category>
		<category><![CDATA[Meredith Corporation]]></category>
		<category><![CDATA[Metrocorp Bancshares Inc.]]></category>
		<category><![CDATA[Micros Systems Inc.]]></category>
		<category><![CDATA[Microsoft Corporation]]></category>
		<category><![CDATA[MKC]]></category>
		<category><![CDATA[MLNX]]></category>
		<category><![CDATA[MMM]]></category>
		<category><![CDATA[MOGA]]></category>
		<category><![CDATA[Molex Inc.]]></category>
		<category><![CDATA[MOLX]]></category>
		<category><![CDATA[Moog Incorporated]]></category>
		<category><![CDATA[Motorola Solutions]]></category>
		<category><![CDATA[MPX]]></category>
		<category><![CDATA[MRTN]]></category>
		<category><![CDATA[MSFT]]></category>
		<category><![CDATA[MSI]]></category>
		<category><![CDATA[MXIM]]></category>
		<category><![CDATA[National Penn Bancshares Inc]]></category>
		<category><![CDATA[NE]]></category>
		<category><![CDATA[Netflix Inc.]]></category>
		<category><![CDATA[NFLX]]></category>
		<category><![CDATA[Noble Corporation]]></category>
		<category><![CDATA[NOK]]></category>
		<category><![CDATA[Nokia Corporation]]></category>
		<category><![CDATA[Norfolk Southern Corporation]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NPBC]]></category>
		<category><![CDATA[NSC]]></category>
		<category><![CDATA[NVE Corporation]]></category>
		<category><![CDATA[NVEC]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[OceanFirst Financial Corporation]]></category>
		<category><![CDATA[OCFC]]></category>
		<category><![CDATA[Old Republic International Corporation]]></category>
		<category><![CDATA[OMN]]></category>
		<category><![CDATA[OMNOVA Solutions Inc.]]></category>
		<category><![CDATA[Open Text Corporation]]></category>
		<category><![CDATA[ORI]]></category>
		<category><![CDATA[Oshkosh Corporation]]></category>
		<category><![CDATA[OSK]]></category>
		<category><![CDATA[OTEX]]></category>
		<category><![CDATA[Pacific Premier Bancorp Inc]]></category>
		<category><![CDATA[Packaging Corporation of America]]></category>
		<category><![CDATA[Parametric Technology Corporation]]></category>
		<category><![CDATA[PCP]]></category>
		<category><![CDATA[PEBO]]></category>
		<category><![CDATA[Peoples Bancorp Inc]]></category>
		<category><![CDATA[PetMed Express Inc.]]></category>
		<category><![CDATA[PETS]]></category>
		<category><![CDATA[PFBC]]></category>
		<category><![CDATA[PG]]></category>
		<category><![CDATA[PKG]]></category>
		<category><![CDATA[PLCM]]></category>
		<category><![CDATA[PMTC]]></category>
		<category><![CDATA[Polycom Inc.]]></category>
		<category><![CDATA[Popular Inc]]></category>
		<category><![CDATA[PPBI]]></category>
		<category><![CDATA[Praxair Inc.]]></category>
		<category><![CDATA[Precision Castparts Corporation]]></category>
		<category><![CDATA[Preferred Bank]]></category>
		<category><![CDATA[Premierwest Bancorp]]></category>
		<category><![CDATA[Privatebancorp Inc]]></category>
		<category><![CDATA[Procter & Gamble Company]]></category>
		<category><![CDATA[PRWT]]></category>
		<category><![CDATA[PVTB]]></category>
		<category><![CDATA[PX]]></category>
		<category><![CDATA[QLGC]]></category>
		<category><![CDATA[QLogic Corporation]]></category>
		<category><![CDATA[QSII]]></category>
		<category><![CDATA[Quality Systems Inc.]]></category>
		<category><![CDATA[Quest Diagnostics Inc.]]></category>
		<category><![CDATA[Raymond James Financial Inc.]]></category>
		<category><![CDATA[Rayonier Inc.]]></category>
		<category><![CDATA[Raytheon Company]]></category>
		<category><![CDATA[Regions Financial Corporation]]></category>
		<category><![CDATA[RES]]></category>
		<category><![CDATA[Resmed Inc]]></category>
		<category><![CDATA[RF]]></category>
		<category><![CDATA[RF Micro Devices Inc.]]></category>
		<category><![CDATA[RFMD]]></category>
		<category><![CDATA[RJF]]></category>
		<category><![CDATA[RKT]]></category>
		<category><![CDATA[RLI]]></category>
		<category><![CDATA[RLI Corporation]]></category>
		<category><![CDATA[RMD]]></category>
		<category><![CDATA[Rock-Tenn Company]]></category>
		<category><![CDATA[ROL]]></category>
		<category><![CDATA[Rollins Inc]]></category>
		<category><![CDATA[RPC Inc.]]></category>
		<category><![CDATA[RTN]]></category>
		<category><![CDATA[RYN]]></category>
		<category><![CDATA[SanDisk Corporation]]></category>
		<category><![CDATA[Sandy Spring Bancorp Inc]]></category>
		<category><![CDATA[SAP]]></category>
		<category><![CDATA[Sap Ag]]></category>
		<category><![CDATA[SASR]]></category>
		<category><![CDATA[SBCF]]></category>
		<category><![CDATA[SBUX]]></category>
		<category><![CDATA[ScanSource Inc.]]></category>
		<category><![CDATA[SCSC]]></category>
		<category><![CDATA[SCSS]]></category>
		<category><![CDATA[Seacoast Banking Corporation of Florida]]></category>
		<category><![CDATA[Sealy Corporation]]></category>
		<category><![CDATA[Select Comfort Corporation]]></category>
		<category><![CDATA[SFNC]]></category>
		<category><![CDATA[SILC]]></category>
		<category><![CDATA[Silicom Limited]]></category>
		<category><![CDATA[Simmons First National Corporation]]></category>
		<category><![CDATA[SMCI]]></category>
		<category><![CDATA[SNDK]]></category>
		<category><![CDATA[SNV]]></category>
		<category><![CDATA[Southwest Airlines Company]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[Stanley Works]]></category>
		<category><![CDATA[Starbucks Corporation]]></category>
		<category><![CDATA[STEL]]></category>
		<category><![CDATA[StellarOne Corporation]]></category>
		<category><![CDATA[Sterling Financial Corporation]]></category>
		<category><![CDATA[STJ]]></category>
		<category><![CDATA[Strattec Security Corporation]]></category>
		<category><![CDATA[STRT]]></category>
		<category><![CDATA[Stryker Corporation]]></category>
		<category><![CDATA[STSA]]></category>
		<category><![CDATA[Super Micro Computer Inc]]></category>
		<category><![CDATA[Supertex Inc.]]></category>
		<category><![CDATA[SUPX]]></category>
		<category><![CDATA[SUSQ]]></category>
		<category><![CDATA[Susquehanna Bancshares Inc]]></category>
		<category><![CDATA[SWK]]></category>
		<category><![CDATA[SYK]]></category>
		<category><![CDATA[Symantec Corporation]]></category>
		<category><![CDATA[SYMC]]></category>
		<category><![CDATA[SYMM]]></category>
		<category><![CDATA[Symmetricom Inc]]></category>
		<category><![CDATA[SYNA]]></category>
		<category><![CDATA[Synaptics Inc]]></category>
		<category><![CDATA[Synovus Financial Corporation]]></category>
		<category><![CDATA[T]]></category>
		<category><![CDATA[TAYC]]></category>
		<category><![CDATA[Taylor Capital Group Inc]]></category>
		<category><![CDATA[TBBK]]></category>
		<category><![CDATA[TCBI]]></category>
		<category><![CDATA[TD AMERITRADE Holding Corporation]]></category>
		<category><![CDATA[TEL]]></category>
		<category><![CDATA[Tempur Pedic International Inc]]></category>
		<category><![CDATA[TER]]></category>
		<category><![CDATA[Teradyne Inc.]]></category>
		<category><![CDATA[Texas Capital BancShares Inc.]]></category>
		<category><![CDATA[Texas Instruments Inc.]]></category>
		<category><![CDATA[Textron Inc.]]></category>
		<category><![CDATA[The Bancorp Inc]]></category>
		<category><![CDATA[The Travelers Companies Inc.]]></category>
		<category><![CDATA[Timken Company]]></category>
		<category><![CDATA[TKR]]></category>
		<category><![CDATA[Total System Services Inc]]></category>
		<category><![CDATA[TPX]]></category>
		<category><![CDATA[TRMK]]></category>
		<category><![CDATA[TRST]]></category>
		<category><![CDATA[TrustCo Bank Corporation NY]]></category>
		<category><![CDATA[Trustmark Corporation]]></category>
		<category><![CDATA[TRV]]></category>
		<category><![CDATA[TSS]]></category>
		<category><![CDATA[TUES]]></category>
		<category><![CDATA[Tuesday Morning Corporation]]></category>
		<category><![CDATA[TWIN]]></category>
		<category><![CDATA[Twin Disc Inc.]]></category>
		<category><![CDATA[TXN]]></category>
		<category><![CDATA[TXT]]></category>
		<category><![CDATA[Tyco Electronics Limited]]></category>
		<category><![CDATA[UCBI]]></category>
		<category><![CDATA[UFI]]></category>
		<category><![CDATA[UMB Financial Corporation]]></category>
		<category><![CDATA[UMBF]]></category>
		<category><![CDATA[UMPQ]]></category>
		<category><![CDATA[Umpqua Holdings Corporation]]></category>
		<category><![CDATA[Unifi Inc]]></category>
		<category><![CDATA[Union Pacific Corporation]]></category>
		<category><![CDATA[United Community Banks Inc]]></category>
		<category><![CDATA[United Rentals Inc]]></category>
		<category><![CDATA[United Technologies Corporation]]></category>
		<category><![CDATA[UNP]]></category>
		<category><![CDATA[UPI]]></category>
		<category><![CDATA[URI]]></category>
		<category><![CDATA[Uroplasty Inc]]></category>
		<category><![CDATA[US Airways Group Inc.]]></category>
		<category><![CDATA[UTX]]></category>
		<category><![CDATA[VAR]]></category>
		<category><![CDATA[Varian Medical Systems Inc]]></category>
		<category><![CDATA[VeriSign Inc.]]></category>
		<category><![CDATA[Verizon Communications Inc.]]></category>
		<category><![CDATA[VLTR]]></category>
		<category><![CDATA[Volterra Semiconductor Corporation]]></category>
		<category><![CDATA[VRSN]]></category>
		<category><![CDATA[VZ]]></category>
		<category><![CDATA[W.W. Grainger Inc]]></category>
		<category><![CDATA[WAL]]></category>
		<category><![CDATA[WAT]]></category>
		<category><![CDATA[Waters Corporation]]></category>
		<category><![CDATA[WCBO]]></category>
		<category><![CDATA[WDC]]></category>
		<category><![CDATA[WellPoint Inc.]]></category>
		<category><![CDATA[West BanCorporation Inc]]></category>
		<category><![CDATA[West Coast Bancorp]]></category>
		<category><![CDATA[Western Alliance Bancorporation]]></category>
		<category><![CDATA[Western Digital Corporation]]></category>
		<category><![CDATA[Weyerhaeuser Company]]></category>
		<category><![CDATA[WIBC]]></category>
		<category><![CDATA[Wilshire Bancorp Inc]]></category>
		<category><![CDATA[WLP]]></category>
		<category><![CDATA[WTBA]]></category>
		<category><![CDATA[WY]]></category>
		<category><![CDATA[Xerox Corporation]]></category>
		<category><![CDATA[XRX]]></category>
		<category><![CDATA[ZZ]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=126708</guid>
		<description><![CDATA[The fourth quarter reporting season gets into high gear this week, with 253 companies coming out with quarterly results, including 83 S&#38;P 500 companies. The earnings season thus far has been relatively uneventful, but we will have a better idea by the end of this week; by then we will have seen 30% of the total fourth quarter reports. While last week was all about banks, the focus this week is on the Technology sector, particularly Apple (AAPL) which reports after the close on Wednesday. The iPhone maker has lost some of its sizzle lately and is expected to see earnings decline from the same period last year. No company grows forever, but it may be premature to write Apple off. Other major Tech companies reporting results this week include ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2013/01/20/aapl-fourth-quarter-2012-earnings-season-gets-into-high-gear-earnings-preview/126708/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OPTR) Optimer Pharmaceuticals&#8217; Dificid Sales Look Good</title>
		<link>http://www.stockbloghub.com/2013/01/15/optr-optimer-pharmaceuticals-dificid-sales-look-good/125846</link>
		<comments>http://www.stockbloghub.com/2013/01/15/optr-optimer-pharmaceuticals-dificid-sales-look-good/125846#comments</comments>
		<pubDate>Tue, 15 Jan 2013 22:10:19 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Cambrex Corporation]]></category>
		<category><![CDATA[CBM]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Optimer Pharmaceuticals Inc]]></category>
		<category><![CDATA[OPTR]]></category>
		<category><![CDATA[Repligen Corporation]]></category>
		<category><![CDATA[RGEN]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=125846</guid>
		<description><![CDATA[Optimer Pharmaceuticals Inc. (OPTR) recently announced its preliminary sales for the fourth quarter and full year 2012. Optimer said that preliminary gross product sales of its only marketed product, Dificid (fidaxomicin), were $74.4 million in the US and Canada for the full year 2012 compared to $24.4 million in 2011. Dificid gross sales for the fourth quarter of 2012 were $21.3 million representing a sequential increase of more than 14.4%. Optimer mentioned that preliminary gross-to-net range for the last quarter of 2012 is expected to be 21.0%–21.5%. Optimer recently (effective from January 3, 2013) increased Dificid’s wholesale acquisition cost by around 5.6%. Moreover, the company announced the launch of a Co-Pay Assistance Program for patients who are commercially insured. Dificid was launched in the US in July 2011 for treating ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2013/01/15/optr-optimer-pharmaceuticals-dificid-sales-look-good/125846/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MRK) Pharmaceuticals and Biotech Stock Outlook &#8211; December 2012 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2012/12/07/mrk-pharmaceuticals-and-biotech-stock-outlook-december-2012-industry-outlook/122969</link>
		<comments>http://www.stockbloghub.com/2012/12/07/mrk-pharmaceuticals-and-biotech-stock-outlook-december-2012-industry-outlook/122969#comments</comments>
		<pubDate>Fri, 07 Dec 2012 22:19:05 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BioSpecifics Technologies Corporation]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[BSTC]]></category>
		<category><![CDATA[Catalyst Pharmaceutical Partners Inc]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[CPRX]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[DENTSPLY International Inc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GAIN]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Gladstone Investment Corporation]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JAZZ]]></category>
		<category><![CDATA[Jazz Pharmaceuticals Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[Medicis Pharmaceutical Corporation]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MRX]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[Optimer Pharmaceuticals Inc]]></category>
		<category><![CDATA[OPTR]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Valeant Pharmaceuticals International]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[VRX]]></category>
		<category><![CDATA[W&T Offshore Inc]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>
		<category><![CDATA[WTI]]></category>
		<category><![CDATA[XRAY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=122969</guid>
		<description><![CDATA[The pharmaceutical industry is slowly showing signs of recovery from one of the biggest patent cliffs in recent times. The last few quarters saw major blockbusters like Merck’s (MRK) Singulair, Pfizer’s (PFE) Lipitor, Forest Laboratories’ (FRX) Lexapro, Sanofi/Bristol-Myers’ (SNY/BMY) Plavix and Eli Lilly’s (LLY) Zyprexa losing patent protection. These products alone represented branded sales worth more than $15 billion. However, the effect of the genericization of these products will be felt mostly in 2012. While the industry won’t be completely free from genericization, the major patent expiries are over and done with. New products should start contributing significantly to results and increased pipeline visibility and appropriate utilization of cash should increase confidence in the sector. M&#38;A Activity The M&#38;A activity witnessed in the pharma sector in the last couple of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/12/07/mrk-pharmaceuticals-and-biotech-stock-outlook-december-2012-industry-outlook/122969/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AZN) AstraZeneca&#8217;s Zinforo Gets European Commission Approval</title>
		<link>http://www.stockbloghub.com/2012/08/31/azn-astrazenecas-zinforo-gets-european-commission-approval/110964</link>
		<comments>http://www.stockbloghub.com/2012/08/31/azn-astrazenecas-zinforo-gets-european-commission-approval/110964#comments</comments>
		<pubDate>Fri, 31 Aug 2012 14:26:20 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[CAI International Inc.]]></category>
		<category><![CDATA[CAP]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[EC]]></category>
		<category><![CDATA[Ecopetrol Sa]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=110964</guid>
		<description><![CDATA[AstraZeneca (AZN) recently announced that the European Commission (EC) has approved Zinforo (ceftaroline fosamil) for treating adults with complicated skin and soft tissue infections (cSSTI) or community acquired pneumonia (CAP). The European approval did not come as a surprise as Zinforo had earlier received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). Approval was based on encouraging data from four phase III trials &#8211; CANVAS 1 and 2 (cSSTI) and FOCUS 1 and 2 (CAP). While we are pleased with the European approval of Zinforo, we note that the market is highly competitive given the presence of players like Cubist Pharmaceutical’s (CBST) Cubicin and Pfizer’s (PFE) Tygacil. We note that in 2009, Forest Laboratories (FRX) had out-licensed co-exclusive development ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/08/31/azn-astrazenecas-zinforo-gets-european-commission-approval/110964/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALNY) Alnylam Pharmaceuticals and Monsanto Collaborate</title>
		<link>http://www.stockbloghub.com/2012/08/30/alny-alnylam-pharmaceuticals-and-monsanto-collaborate/110808</link>
		<comments>http://www.stockbloghub.com/2012/08/30/alny-alnylam-pharmaceuticals-and-monsanto-collaborate/110808#comments</comments>
		<pubDate>Thu, 30 Aug 2012 16:09:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[International Paper Company]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[MON]]></category>
		<category><![CDATA[Monsanto Company]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=110808</guid>
		<description><![CDATA[Alnylam Pharmaceuticals, Inc. (ALNY) and Monsanto Company (MON) recently formed a strategic alliance to implement biological technologies in the field of agriculture. As per the alliance, Alnylam’s broad RNAi-based (ribo nucleic acid interference) intellectual property (IP) and proprietary technologies along with Monsanto’s new BioDirect technology will help deliver innovative biological solutions to farmers. The Agreement As per the terms of the agreement, Monsanto, a leading global provider of technology-based solutions and agricultural products, will acquire worldwide, exclusive rights to use Alnylam’s technologies in the field of agriculture. Monsanto will be able to grant sub-licenses as well. Alnylam will receive $29.2 million in upfront payments, along with milestone payments and other additional funding from Monsanto. The agreement also allows Alnylam to receive royalty payments on the products that will utilize the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/08/30/alny-alnylam-pharmaceuticals-and-monsanto-collaborate/110808/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALNY) Alnylam Pharmaceuticals Earns Milestone Payment</title>
		<link>http://www.stockbloghub.com/2012/08/21/alny-alnylam-pharmaceuticals-earns-milestone-payment/107691</link>
		<comments>http://www.stockbloghub.com/2012/08/21/alny-alnylam-pharmaceuticals-earns-milestone-payment/107691#comments</comments>
		<pubDate>Tue, 21 Aug 2012 21:11:00 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=107691</guid>
		<description><![CDATA[Alnylam Pharmaceuticals Inc. (ALNY) recently earned development milestone payment of $3.2 million from GlaxoSmithKline (GSK). The payment was earned due to the progress on the use of their VaxiRNA technology for producing Glaxo’s influenza vaccines. Alnylam has been a leader in the ribo nucleic acid interference (RNAi) technology and its VaxiRNA platform uses the technology to produce more vaccines. Notably, in November last year, Alnylam and Glaxo entered into a collaboration agreement, which permits Glaxo to use Alnylam’s VaxiRNA technology for producing vaccines. Glaxo, the leading producer of vaccines, is first to utilize Alnylam’s novel VaxiRNA platform for vaccine production. The collaboration agreement focused primarily on influenza vaccine production in cell culture systems. Apart from the $3.2 million received as milestone payment, Alnylam is also eligible to receive payments on ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/08/21/alny-alnylam-pharmaceuticals-earns-milestone-payment/107691/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PFE) Pharma and Biotech Stock Outlook &#8211; August 2012 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2012/08/10/pfe-pharma-biotech-stock-outlook-august-2012-industry-outlook/108031</link>
		<comments>http://www.stockbloghub.com/2012/08/10/pfe-pharma-biotech-stock-outlook-august-2012-industry-outlook/108031#comments</comments>
		<pubDate>Fri, 10 Aug 2012 18:00:38 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Allos Therapeutics Inc.]]></category>
		<category><![CDATA[ALTH]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[Auxilium Pharmaceuticals Inc.]]></category>
		<category><![CDATA[AUXL]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Cardiome Pharma Corporation]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[CRME]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[DENTSPLY International Inc]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GAIN]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Gladstone Investment Corporation]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HGSI]]></category>
		<category><![CDATA[Human Genome Sciences Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[MDVN]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[Medivation Inc]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[Optimer Pharmaceuticals Inc]]></category>
		<category><![CDATA[OPTR]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Spectrum Pharmaceuticals Inc.]]></category>
		<category><![CDATA[SPPI]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[United Therapeutics Corporation]]></category>
		<category><![CDATA[UTHR]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>
		<category><![CDATA[XRAY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=108031</guid>
		<description><![CDATA[The pharmaceutical industry is in the midst of one of the biggest patent cliffs with Pfizer’s (PFE) multi-billion-dollar blockbuster drug Lipitor losing patent protection in the US in late November 2011. Besides Lipitor, other major branded drugs that lost patent protection in the past few months include Forest Laboratories’ (FRX) Lexapro, Sanofi/Bristol-Myers’ (SNY/BMY) Plavix and Eli Lilly’s (LLY) Zyprexa. These products alone represented branded sales worth more than $15 billion. Another product that will start facing generic competition shortly is Merck’s (MRK) blockbuster Singulair. The effect of the genericization of these products will be felt mostly in 2012, which will be a challenging year for several companies. While generics will eat into sales, new products are not expected to generate the same level of sales as products losing patent protection. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/08/10/pfe-pharma-biotech-stock-outlook-august-2012-industry-outlook/108031/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALNY) Alnylam States Preclinical Data</title>
		<link>http://www.stockbloghub.com/2012/01/03/alny-alnylam-states-preclinical-data/89523</link>
		<comments>http://www.stockbloghub.com/2012/01/03/alny-alnylam-states-preclinical-data/89523#comments</comments>
		<pubDate>Tue, 03 Jan 2012 19:15:26 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[HD]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[The Home Depot Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=89523</guid>
		<description><![CDATA[Alnylam Pharmaceuticals Inc (ALNY) recently announced pre-clinical data from a trial evaluating its pipeline candidate ALN-HTT for the treatment of Huntington&#8217;s disease (HD). ALN-HTT is a novel therapeutic product that uses the potentially revolutionary RNA (ribo nucleic acid) interference (RNAi) technology. The data showed broad central nervous system (CNS) distribution and robust therapeutic silencing of the gene responsible for Huntington&#8217;s disease. Further, ALN-HTT was well tolerated in these studies. ALN-HTT is being developed in collaboration with Medtronic, Inc. (MDT) and the CHDI Foundation. Alnylam expects to file an investigational new drug application (IND) application for the candidate in 2012. Approval of the IND by the US Food &#38; Drug Administration (FDA) will allow the candidate to enter early stage clinical trials. Besides ALN-HTT, Alnylam is developing ALN-RSV01 for the treatment ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/03/alny-alnylam-states-preclinical-data/89523/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OPTR) Optimer Pharmaceuticals Dificlir Cleared in European Union</title>
		<link>http://www.stockbloghub.com/2011/12/15/optr-optimer-pharmaceuticals-dificlir-cleared-in-european-union/88596</link>
		<comments>http://www.stockbloghub.com/2011/12/15/optr-optimer-pharmaceuticals-dificlir-cleared-in-european-union/88596#comments</comments>
		<pubDate>Thu, 15 Dec 2011 10:00:22 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[CDI]]></category>
		<category><![CDATA[CDI Corporation]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Optimer Pharmaceuticals Inc]]></category>
		<category><![CDATA[OPTR]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88596</guid>
		<description><![CDATA[Optimer Pharmaceuticals, Inc. (OPTR) and partner Astellas Pharma recently announced that their antibiotic Dificlir received approval in the European Union (EU), not belying expectations. The European Medicines Agency (EMA) cleared Dificlir for the treatment of clostridium difficile-associated diarrhea (CDAD) also known as clostridium difficile infection (CDI). CDAD is the most common nosocomial or hospital-acquired diarrhea and is a significant malaise in hospitals and nursing home facilities. The EU approval does not surprise us since in September this year Dificlir received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the EMA. Dificlir is already marketed as Dificid in the US for CDAD in partnership with Cubist Pharmaceuticals, Inc. (CBST). The European regulatory body’s decision was based on data from two late stage studies which showed ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/15/optr-optimer-pharmaceuticals-dificlir-cleared-in-european-union/88596/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALNY) Alnylam Pharmaceuticals Analyst Still Bullish</title>
		<link>http://www.stockbloghub.com/2011/12/08/alny-alnylam-pharmaceuticals-analyst-still-bullish/88197</link>
		<comments>http://www.stockbloghub.com/2011/12/08/alny-alnylam-pharmaceuticals-analyst-still-bullish/88197#comments</comments>
		<pubDate>Thu, 08 Dec 2011 17:05:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88197</guid>
		<description><![CDATA[We have maintained an Outperform rating on Alnylam Pharmaceuticals, Inc (ALNY) with a target price of $8.25 per share following appraisal of third quarter 2011 results. Alnylam Pharmaceuticals Inc. is a biopharmaceutical company developing novel therapeutics based on a biological breakthrough technology known as RNA (Ribo Nucleic Acid) interference (RNAi). Alnylam is currently utilizing this know-how to build a pipeline of drug candidates for the treatment of a wide array of diseases. Alnylam’s third quarter 2011 loss of 31 cents per share was narrower than the Zacks Consensus Estimate of a loss 36 cents per share. Lower operating expenses led to the narrower loss despite lukewarm revenues in the quarter. The loss was, however, wider than the year-ago loss of $0.23 per share. Revenues for the reported quarter fell 24.9% ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/08/alny-alnylam-pharmaceuticals-analyst-still-bullish/88197/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALNY) Alnylam Pharmaceuticals Completes Trial Enrollment</title>
		<link>http://www.stockbloghub.com/2011/12/02/alny-alnylam-pharmaceuticals-completes-trial-enrollment/87898</link>
		<comments>http://www.stockbloghub.com/2011/12/02/alny-alnylam-pharmaceuticals-completes-trial-enrollment/87898#comments</comments>
		<pubDate>Fri, 02 Dec 2011 16:19:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87898</guid>
		<description><![CDATA[Alnylam Pharmaceuticals Inc. (ALNY) recently announced it has completed enrollment in a mid-stage study of its pipeline candidate ALN-RSV01, an RNA interference technology (RNAi) therapeutic being studied for the treatment of respiratory syncytial virus (RSV) infection. The study is being conducted in RSV-infected lung transplant patients at 33 lung transplant centers in six countries. Data from the study is expected in mid-2012. Alnylam is developing ALN-RSV01 on its own while Cubist Pharmaceuticals (CBST) has the opt-in right to collaborate with the company in future for the lung transplant indication. Kyowa Hakko Kirin has opt-in rights for the candidate in Asia. Alnylam’s RNAi technology is potentially revolutionary. Alnylam is utilizing this know-how for selectively turning off the activity of certain genes to build a pipeline of drug candidates to treat a ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/02/alny-alnylam-pharmaceuticals-completes-trial-enrollment/87898/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALNY) Alnylam Pharmaceuticals Reveals ALNTTR01 Trial Data</title>
		<link>http://www.stockbloghub.com/2011/11/28/alny-alnylam-pharmaceuticals-reveals-alnttr01-trial-data/87547</link>
		<comments>http://www.stockbloghub.com/2011/11/28/alny-alnylam-pharmaceuticals-reveals-alnttr01-trial-data/87547#comments</comments>
		<pubDate>Mon, 28 Nov 2011 16:32:53 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87547</guid>
		<description><![CDATA[Alnylam Pharmaceuticals Inc. (ALNY) recently presented data from an early stage study of its pipeline candidate ALN-TTR01 at a scientific conference in Japan. ALN-TTR01 is a systemically delivered RNA interference technology (RNAi) therapeutic that employs a first-generation lipid nanoparticles (LNP) formulation to treat transthyretin (TTR) mediated amyloidosis (ATTR). Data from the trials showed that ALN-TTR01 led to statistically significant reductions in serum TTR protein levels for the treatment of ATTR. Overall, the candidate has proved to be well tolerated with no serious adverse events observed in the study. We believe the encouraging data further highlights the potential of RNAi as a new class of therapeutics. This is the first time an RNAi has silenced a disease-causing gene in clinical trials. ALN-TTR01 is part of Alnylam’s core product strategy, Alnylam 5&#215;15, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/28/alny-alnylam-pharmaceuticals-reveals-alnttr01-trial-data/87547/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AAPL) A Busy Week Ahead &#8211; Earnings Preview</title>
		<link>http://www.stockbloghub.com/2011/10/17/aapl-a-busy-week-ahead-earnings-preview/85152</link>
		<comments>http://www.stockbloghub.com/2011/10/17/aapl-a-busy-week-ahead-earnings-preview/85152#comments</comments>
		<pubDate>Mon, 17 Oct 2011 15:31:27 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Personal Computers]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[8x8 Inc]]></category>
		<category><![CDATA[AAPL]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Acacia Research Corporation]]></category>
		<category><![CDATA[Access National Corporation]]></category>
		<category><![CDATA[Acme Packet Inc]]></category>
		<category><![CDATA[ACTG]]></category>
		<category><![CDATA[ADS]]></category>
		<category><![CDATA[AF]]></category>
		<category><![CDATA[Air Products & Chemicals Inc.]]></category>
		<category><![CDATA[Alaska Air Group Inc.]]></category>
		<category><![CDATA[Alexion Pharmaceuticals Inc]]></category>
		<category><![CDATA[ALK]]></category>
		<category><![CDATA[Alliance Data Systems Corporation]]></category>
		<category><![CDATA[Alliance Financial Corporation]]></category>
		<category><![CDATA[ALNC]]></category>
		<category><![CDATA[Altera Corporation]]></category>
		<category><![CDATA[ALTR]]></category>
		<category><![CDATA[ALXN]]></category>
		<category><![CDATA[American Express Company]]></category>
		<category><![CDATA[American River Bankshares]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amphenol Corporation]]></category>
		<category><![CDATA[AMR]]></category>
		<category><![CDATA[AMR Corporation]]></category>
		<category><![CDATA[AMRB]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[AN]]></category>
		<category><![CDATA[ANCX]]></category>
		<category><![CDATA[AO Smith Corporation]]></category>
		<category><![CDATA[AOS]]></category>
		<category><![CDATA[APD]]></category>
		<category><![CDATA[APH]]></category>
		<category><![CDATA[APKT]]></category>
		<category><![CDATA[APOL]]></category>
		<category><![CDATA[Apollo Group Inc.]]></category>
		<category><![CDATA[Apple Inc.]]></category>
		<category><![CDATA[ASBC]]></category>
		<category><![CDATA[ASR]]></category>
		<category><![CDATA[Associated Banc-Corp]]></category>
		<category><![CDATA[Astoria Financial Corporation]]></category>
		<category><![CDATA[AT&T Inc.]]></category>
		<category><![CDATA[Athenahealth Inc]]></category>
		<category><![CDATA[ATHN]]></category>
		<category><![CDATA[ATMI]]></category>
		<category><![CDATA[ATMI Inc.]]></category>
		<category><![CDATA[AutoNation Inc.]]></category>
		<category><![CDATA[AXP]]></category>
		<category><![CDATA[BAC]]></category>
		<category><![CDATA[Badger Meter Inc]]></category>
		<category><![CDATA[Bank of America Corporation]]></category>
		<category><![CDATA[Banner Corporation]]></category>
		<category><![CDATA[BANR]]></category>
		<category><![CDATA[BAS]]></category>
		<category><![CDATA[Basic Energy Services Inc.]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International Inc]]></category>
		<category><![CDATA[BB & T Corporation]]></category>
		<category><![CDATA[BBND]]></category>
		<category><![CDATA[BBT]]></category>
		<category><![CDATA[BGG]]></category>
		<category><![CDATA[BigBand Networks Inc]]></category>
		<category><![CDATA[BJ's Restaurants Inc.]]></category>
		<category><![CDATA[BJRI]]></category>
		<category><![CDATA[BK]]></category>
		<category><![CDATA[BlackRock Inc.]]></category>
		<category><![CDATA[BLDR]]></category>
		<category><![CDATA[BLK]]></category>
		<category><![CDATA[BMI]]></category>
		<category><![CDATA[BOOT]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[Bottomline Technologies Inc]]></category>
		<category><![CDATA[BPOP]]></category>
		<category><![CDATA[Briggs & Stratton Corporation]]></category>
		<category><![CDATA[BRKL]]></category>
		<category><![CDATA[BRO]]></category>
		<category><![CDATA[Brookline Bancorp Inc]]></category>
		<category><![CDATA[Brown & Brown Inc.]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[Buffalo Wild Wings Inc.]]></category>
		<category><![CDATA[Builders FirstSource Inc]]></category>
		<category><![CDATA[BWLD]]></category>
		<category><![CDATA[BX]]></category>
		<category><![CDATA[C]]></category>
		<category><![CDATA[CAKE]]></category>
		<category><![CDATA[Capital One Financial Corporation]]></category>
		<category><![CDATA[Cardinal Financial Corporation]]></category>
		<category><![CDATA[Cash America International Inc]]></category>
		<category><![CDATA[Cathay General Bancorp]]></category>
		<category><![CDATA[CATY]]></category>
		<category><![CDATA[CB]]></category>
		<category><![CDATA[CBE]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[CCK]]></category>
		<category><![CDATA[Central Valley Community Bancorp]]></category>
		<category><![CDATA[Cepheid]]></category>
		<category><![CDATA[CFNL]]></category>
		<category><![CDATA[Charles Schwab Corporation]]></category>
		<category><![CDATA[Check Point Software Technologies Limited]]></category>
		<category><![CDATA[Chipotle Mexican Grill Inc.]]></category>
		<category><![CDATA[CHKP]]></category>
		<category><![CDATA[Cirrus Logic Inc.]]></category>
		<category><![CDATA[Citigroup Inc.]]></category>
		<category><![CDATA[City National Corporation]]></category>
		<category><![CDATA[CKH]]></category>
		<category><![CDATA[CLB]]></category>
		<category><![CDATA[CMA]]></category>
		<category><![CDATA[CMG]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[CoBiz Financial Inc]]></category>
		<category><![CDATA[COBZ]]></category>
		<category><![CDATA[COF]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[COHU]]></category>
		<category><![CDATA[Cohu Inc]]></category>
		<category><![CDATA[Comerica Incorporated]]></category>
		<category><![CDATA[Community Trust Bancorp Inc]]></category>
		<category><![CDATA[Complete Production Services Inc]]></category>
		<category><![CDATA[Compuware Corporation]]></category>
		<category><![CDATA[Cooper Industries Limited]]></category>
		<category><![CDATA[Core Laboratories NV]]></category>
		<category><![CDATA[Covanta Holding Corporation]]></category>
		<category><![CDATA[CPHD]]></category>
		<category><![CDATA[CPWR]]></category>
		<category><![CDATA[CPX]]></category>
		<category><![CDATA[CREE]]></category>
		<category><![CDATA[Cree Inc.]]></category>
		<category><![CDATA[Crown Holdings Inc.]]></category>
		<category><![CDATA[CRUS]]></category>
		<category><![CDATA[CSH]]></category>
		<category><![CDATA[CSX]]></category>
		<category><![CDATA[CSX Corporation]]></category>
		<category><![CDATA[CTBI]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[CVA]]></category>
		<category><![CDATA[CVB Financial Corporation]]></category>
		<category><![CDATA[CVBF]]></category>
		<category><![CDATA[CVCY]]></category>
		<category><![CDATA[CY]]></category>
		<category><![CDATA[Cymer Inc.]]></category>
		<category><![CDATA[CYMI]]></category>
		<category><![CDATA[CYN]]></category>
		<category><![CDATA[Cypress Semiconductor Corporation]]></category>
		<category><![CDATA[CYT]]></category>
		<category><![CDATA[Cytec Industries Inc.]]></category>
		<category><![CDATA[Danaher Corporation]]></category>
		<category><![CDATA[Datalink Corporation]]></category>
		<category><![CDATA[DHR]]></category>
		<category><![CDATA[Diamond Offshore Drilling Inc]]></category>
		<category><![CDATA[Diamondrock Hospitality Company]]></category>
		<category><![CDATA[DO]]></category>
		<category><![CDATA[Dominos Pizza Inc.]]></category>
		<category><![CDATA[DOV]]></category>
		<category><![CDATA[Dover Corporation]]></category>
		<category><![CDATA[DPZ]]></category>
		<category><![CDATA[DRH]]></category>
		<category><![CDATA[DTLK]]></category>
		<category><![CDATA[E*TRADE Financial Corporation]]></category>
		<category><![CDATA[East West Bancorp Inc]]></category>
		<category><![CDATA[EastGroup Properties Inc]]></category>
		<category><![CDATA[EBAY]]></category>
		<category><![CDATA[eBay Inc.]]></category>
		<category><![CDATA[ECA]]></category>
		<category><![CDATA[EDU]]></category>
		<category><![CDATA[Edwards Lifesciences Corporation]]></category>
		<category><![CDATA[EFII]]></category>
		<category><![CDATA[EGHT]]></category>
		<category><![CDATA[EGP]]></category>
		<category><![CDATA[Electronics for Imaging Inc.]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[ELS]]></category>
		<category><![CDATA[EMC]]></category>
		<category><![CDATA[EMC Corporation]]></category>
		<category><![CDATA[Encana Corporation]]></category>
		<category><![CDATA[ENZ]]></category>
		<category><![CDATA[Enzo Biochem Inc]]></category>
		<category><![CDATA[EPAY]]></category>
		<category><![CDATA[Equity Lifestyles Properties Inc]]></category>
		<category><![CDATA[ERIC]]></category>
		<category><![CDATA[ESI]]></category>
		<category><![CDATA[ETFC]]></category>
		<category><![CDATA[EW]]></category>
		<category><![CDATA[EWBC]]></category>
		<category><![CDATA[EXPO]]></category>
		<category><![CDATA[Exponent Inc.]]></category>
		<category><![CDATA[F.N.B. Corporation]]></category>
		<category><![CDATA[FCFS]]></category>
		<category><![CDATA[FCX]]></category>
		<category><![CDATA[FFIN]]></category>
		<category><![CDATA[FHN]]></category>
		<category><![CDATA[Fidelity National Financial Inc]]></category>
		<category><![CDATA[Fifth Third Bancorp]]></category>
		<category><![CDATA[First Cash Financial Services Inc]]></category>
		<category><![CDATA[First Financial Bankshares Inc]]></category>
		<category><![CDATA[First Horizon National Corporation]]></category>
		<category><![CDATA[First Niagara Financial Group Inc]]></category>
		<category><![CDATA[FITB]]></category>
		<category><![CDATA[FLEX]]></category>
		<category><![CDATA[Flexsteel Industries Inc]]></category>
		<category><![CDATA[Flextronics International Limited]]></category>
		<category><![CDATA[FLIR]]></category>
		<category><![CDATA[FLIR Systems Inc]]></category>
		<category><![CDATA[FLXS]]></category>
		<category><![CDATA[FNB]]></category>
		<category><![CDATA[FNF]]></category>
		<category><![CDATA[FNFG]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[Forward Air Corporation]]></category>
		<category><![CDATA[Freeport-McMoRan Copper & Gold Inc]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[FSI International Inc]]></category>
		<category><![CDATA[FSII]]></category>
		<category><![CDATA[FULT]]></category>
		<category><![CDATA[Fulton Financial Corporation]]></category>
		<category><![CDATA[FWRD]]></category>
		<category><![CDATA[Gannett Company Inc]]></category>
		<category><![CDATA[Gardner Denver Inc.]]></category>
		<category><![CDATA[GATX Corporation]]></category>
		<category><![CDATA[GCI]]></category>
		<category><![CDATA[GDI]]></category>
		<category><![CDATA[GE]]></category>
		<category><![CDATA[General Electric Company]]></category>
		<category><![CDATA[Gentex Corporation]]></category>
		<category><![CDATA[Genuine Parts Company]]></category>
		<category><![CDATA[GHL]]></category>
		<category><![CDATA[GLF]]></category>
		<category><![CDATA[GMT]]></category>
		<category><![CDATA[GNTX]]></category>
		<category><![CDATA[Goldman Sachs Group]]></category>
		<category><![CDATA[GPC]]></category>
		<category><![CDATA[Greenhill & Co Inc.]]></category>
		<category><![CDATA[Grupo Aeroportuario Del Sureste SA de CV]]></category>
		<category><![CDATA[GS]]></category>
		<category><![CDATA[Gulfmark Offshore Inc.]]></category>
		<category><![CDATA[GWW]]></category>
		<category><![CDATA[HA]]></category>
		<category><![CDATA[HAFC]]></category>
		<category><![CDATA[HAL]]></category>
		<category><![CDATA[Halliburton Company]]></category>
		<category><![CDATA[Hanesbrands Inc.]]></category>
		<category><![CDATA[Hanmi Financial Corporation]]></category>
		<category><![CDATA[HAR]]></category>
		<category><![CDATA[Harley-Davidson Inc.]]></category>
		<category><![CDATA[Harman International Industries Inc]]></category>
		<category><![CDATA[HAS]]></category>
		<category><![CDATA[Hasbro Inc.]]></category>
		<category><![CDATA[Hawaiian Holdings Inc.]]></category>
		<category><![CDATA[HBAN]]></category>
		<category><![CDATA[HBI]]></category>
		<category><![CDATA[HCBK]]></category>
		<category><![CDATA[HCCI]]></category>
		<category><![CDATA[Heartland Express Inc]]></category>
		<category><![CDATA[Heritage-Crystal Clean Inc]]></category>
		<category><![CDATA[HITT]]></category>
		<category><![CDATA[Hittite Microwave Corporation]]></category>
		<category><![CDATA[HNI]]></category>
		<category><![CDATA[HNI Corporation]]></category>
		<category><![CDATA[HOG]]></category>
		<category><![CDATA[HOMB]]></category>
		<category><![CDATA[Home Bancshares Inc (Conway AR)]]></category>
		<category><![CDATA[HON]]></category>
		<category><![CDATA[Honeywell International Inc.]]></category>
		<category><![CDATA[HTLD]]></category>
		<category><![CDATA[HUBB]]></category>
		<category><![CDATA[Hubbell Inc B Shares]]></category>
		<category><![CDATA[Hudson City Bancorp Inc]]></category>
		<category><![CDATA[Huntington Bancshares Inc]]></category>
		<category><![CDATA[IBKR]]></category>
		<category><![CDATA[IBM]]></category>
		<category><![CDATA[ICLR]]></category>
		<category><![CDATA[ICON plc]]></category>
		<category><![CDATA[ICU Medical Inc]]></category>
		<category><![CDATA[ICUI]]></category>
		<category><![CDATA[IDEX Corporation]]></category>
		<category><![CDATA[IDEXX Laboratories Inc.]]></category>
		<category><![CDATA[IDXX]]></category>
		<category><![CDATA[IEX]]></category>
		<category><![CDATA[IIIN]]></category>
		<category><![CDATA[INDB]]></category>
		<category><![CDATA[Independent Bank Corporation]]></category>
		<category><![CDATA[INFA]]></category>
		<category><![CDATA[Infinera Corporation]]></category>
		<category><![CDATA[INFN]]></category>
		<category><![CDATA[Informatica Corporation]]></category>
		<category><![CDATA[Ingersoll-Rand Company Limited]]></category>
		<category><![CDATA[Insteel Industries Inc.]]></category>
		<category><![CDATA[INTC]]></category>
		<category><![CDATA[Intel Corporation]]></category>
		<category><![CDATA[Interactive Brokers Group Inc]]></category>
		<category><![CDATA[International Business Machines]]></category>
		<category><![CDATA[Intuitive Surgical Inc]]></category>
		<category><![CDATA[IR]]></category>
		<category><![CDATA[ISRG]]></category>
		<category><![CDATA[ITT Educational Services Inc.]]></category>
		<category><![CDATA[Ixia]]></category>
		<category><![CDATA[JAKK]]></category>
		<category><![CDATA[JAKKS Pacific Inc.]]></category>
		<category><![CDATA[Janus Capital Group Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[JNPR]]></category>
		<category><![CDATA[JNS]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Journal Communications Inc.]]></category>
		<category><![CDATA[JRN]]></category>
		<category><![CDATA[Juniper Networks Inc.]]></category>
		<category><![CDATA[Kansas City Southern]]></category>
		<category><![CDATA[Kayne Anderson Energy Development Company]]></category>
		<category><![CDATA[KCI]]></category>
		<category><![CDATA[KED]]></category>
		<category><![CDATA[Kensey Nash Corporation]]></category>
		<category><![CDATA[KEY]]></category>
		<category><![CDATA[KeyCorp]]></category>
		<category><![CDATA[Kinder Morgan Energy Partners LP]]></category>
		<category><![CDATA[Kinder Morgan Management LLC]]></category>
		<category><![CDATA[Kinetic Concepts Inc]]></category>
		<category><![CDATA[KMP]]></category>
		<category><![CDATA[KMR]]></category>
		<category><![CDATA[Knight Transportation Inc]]></category>
		<category><![CDATA[KNL]]></category>
		<category><![CDATA[Knoll Inc.]]></category>
		<category><![CDATA[KNSY]]></category>
		<category><![CDATA[KNX]]></category>
		<category><![CDATA[KO]]></category>
		<category><![CDATA[Koninklijke Philips Electronics NV]]></category>
		<category><![CDATA[KSU]]></category>
		<category><![CDATA[Laboratory Corporation of America Holdings]]></category>
		<category><![CDATA[Lacrosse Footwear Inc.]]></category>
		<category><![CDATA[Lakeland Bancorp Inc]]></category>
		<category><![CDATA[Lam Research Corporation]]></category>
		<category><![CDATA[Lare Holdings Inc]]></category>
		<category><![CDATA[LaSalle Hotel Properties]]></category>
		<category><![CDATA[Lattice Semiconductor Corporation]]></category>
		<category><![CDATA[LBAI]]></category>
		<category><![CDATA[LCC]]></category>
		<category><![CDATA[LH]]></category>
		<category><![CDATA[LHO]]></category>
		<category><![CDATA[Life Time Fitness Inc.]]></category>
		<category><![CDATA[Linear Technology Corporation]]></category>
		<category><![CDATA[LLTC]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Lm Ericsson Telephone Company]]></category>
		<category><![CDATA[LNCR]]></category>
		<category><![CDATA[LRCX]]></category>
		<category><![CDATA[LSCC]]></category>
		<category><![CDATA[LTM]]></category>
		<category><![CDATA[LUFK]]></category>
		<category><![CDATA[Lufkin Industries Inc.]]></category>
		<category><![CDATA[LUV]]></category>
		<category><![CDATA[M&T Bank Corporation]]></category>
		<category><![CDATA[MAN]]></category>
		<category><![CDATA[MANH]]></category>
		<category><![CDATA[Manhattan Associates Inc.]]></category>
		<category><![CDATA[Manpower Inc.]]></category>
		<category><![CDATA[Marten Transport Limited]]></category>
		<category><![CDATA[Mattson Technology Inc]]></category>
		<category><![CDATA[Maxim Integrated Products Inc]]></category>
		<category><![CDATA[Mb Financial Inc]]></category>
		<category><![CDATA[MBFI]]></category>
		<category><![CDATA[MBWM]]></category>
		<category><![CDATA[MCD]]></category>
		<category><![CDATA[McDonald's Corporation]]></category>
		<category><![CDATA[McMoRan Exploration Company]]></category>
		<category><![CDATA[MCRI]]></category>
		<category><![CDATA[Mercantile Bank Corporation]]></category>
		<category><![CDATA[MGIC Investment Corporation]]></category>
		<category><![CDATA[MHP]]></category>
		<category><![CDATA[Microsoft Corporation]]></category>
		<category><![CDATA[MKS Instruments Inc.]]></category>
		<category><![CDATA[MKSI]]></category>
		<category><![CDATA[MMR]]></category>
		<category><![CDATA[MNI]]></category>
		<category><![CDATA[MNRO]]></category>
		<category><![CDATA[Monarch Casino & Resort Inc.]]></category>
		<category><![CDATA[Monro Muffler Brake Inc.]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MRTN]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[MSFT]]></category>
		<category><![CDATA[MTB]]></category>
		<category><![CDATA[MTG]]></category>
		<category><![CDATA[MTSN]]></category>
		<category><![CDATA[MXIM]]></category>
		<category><![CDATA[MYE]]></category>
		<category><![CDATA[Myers Industries Inc.]]></category>
		<category><![CDATA[NBL]]></category>
		<category><![CDATA[NE]]></category>
		<category><![CDATA[NetScout Systems Inc]]></category>
		<category><![CDATA[New Oriental Education & Technology Group]]></category>
		<category><![CDATA[New York Community Bancorp Inc]]></category>
		<category><![CDATA[Newfield Exploration Company]]></category>
		<category><![CDATA[NFX]]></category>
		<category><![CDATA[Noble Corporation]]></category>
		<category><![CDATA[Noble Energy Inc]]></category>
		<category><![CDATA[NOK]]></category>
		<category><![CDATA[Nokia Corporation]]></category>
		<category><![CDATA[Northern Trust Corporation]]></category>
		<category><![CDATA[NTCT]]></category>
		<category><![CDATA[NTRS]]></category>
		<category><![CDATA[Nucor Corporation]]></category>
		<category><![CDATA[NUE]]></category>
		<category><![CDATA[NVE Corporation]]></category>
		<category><![CDATA[NVEC]]></category>
		<category><![CDATA[NVR]]></category>
		<category><![CDATA[NVR Inc.]]></category>
		<category><![CDATA[NYB]]></category>
		<category><![CDATA[NYT]]></category>
		<category><![CDATA[OceanFirst Financial Corporation]]></category>
		<category><![CDATA[OCFC]]></category>
		<category><![CDATA[OKSB]]></category>
		<category><![CDATA[OMC]]></category>
		<category><![CDATA[Omnicom Group Inc.]]></category>
		<category><![CDATA[ORB]]></category>
		<category><![CDATA[Orbital Sciences Corporation]]></category>
		<category><![CDATA[Pacific Continental Corporation]]></category>
		<category><![CDATA[Packaging Corporation of America]]></category>
		<category><![CDATA[Park National Corporation]]></category>
		<category><![CDATA[Parker Hannifin Corporation]]></category>
		<category><![CDATA[Patni Computer Systems Limited]]></category>
		<category><![CDATA[Patriot Coal Corporation]]></category>
		<category><![CDATA[PBCT]]></category>
		<category><![CDATA[PCBK]]></category>
		<category><![CDATA[PCX]]></category>
		<category><![CDATA[PDS]]></category>
		<category><![CDATA[PENN]]></category>
		<category><![CDATA[Penn National Gaming Inc.]]></category>
		<category><![CDATA[Peoples United Financial Inc]]></category>
		<category><![CDATA[PetMed Express Inc.]]></category>
		<category><![CDATA[PETS]]></category>
		<category><![CDATA[PFBC]]></category>
		<category><![CDATA[PGI]]></category>
		<category><![CDATA[PH]]></category>
		<category><![CDATA[PHG]]></category>
		<category><![CDATA[Philip Morris International Inc]]></category>
		<category><![CDATA[PII]]></category>
		<category><![CDATA[Pinnacle Financial Partners Inc]]></category>
		<category><![CDATA[Piper Jaffray Companies]]></category>
		<category><![CDATA[Pixelworks Inc]]></category>
		<category><![CDATA[PJC]]></category>
		<category><![CDATA[PKG]]></category>
		<category><![CDATA[Platinum Underwriters Holdings Limited]]></category>
		<category><![CDATA[PLCM]]></category>
		<category><![CDATA[PM]]></category>
		<category><![CDATA[PNC]]></category>
		<category><![CDATA[PNC Financial Services Group Inc]]></category>
		<category><![CDATA[PNFP]]></category>
		<category><![CDATA[Polaris Industries Inc.]]></category>
		<category><![CDATA[Polycom Inc.]]></category>
		<category><![CDATA[POOL]]></category>
		<category><![CDATA[Pool Corp]]></category>
		<category><![CDATA[Popular Inc]]></category>
		<category><![CDATA[PPG]]></category>
		<category><![CDATA[PPG Industries Inc.]]></category>
		<category><![CDATA[Precision Drilling Trust]]></category>
		<category><![CDATA[Preferred Bank]]></category>
		<category><![CDATA[Premiere Global Services Inc.]]></category>
		<category><![CDATA[PRK]]></category>
		<category><![CDATA[Prosperity Bancshares Inc.]]></category>
		<category><![CDATA[PRSP]]></category>
		<category><![CDATA[PTI]]></category>
		<category><![CDATA[PTP]]></category>
		<category><![CDATA[PXLW]]></category>
		<category><![CDATA[Rambus Inc.]]></category>
		<category><![CDATA[Raymond James Financial Inc.]]></category>
		<category><![CDATA[RCKY]]></category>
		<category><![CDATA[Renaissance Learning Inc.]]></category>
		<category><![CDATA[Renasant Corporation]]></category>
		<category><![CDATA[RHI]]></category>
		<category><![CDATA[Riverbed Technology Inc.]]></category>
		<category><![CDATA[RJF]]></category>
		<category><![CDATA[RLI]]></category>
		<category><![CDATA[RLI Corporation]]></category>
		<category><![CDATA[RLRN]]></category>
		<category><![CDATA[RMBS]]></category>
		<category><![CDATA[RNST]]></category>
		<category><![CDATA[Robert Half International Inc.]]></category>
		<category><![CDATA[ROC]]></category>
		<category><![CDATA[Rockwood Holdings Inc.]]></category>
		<category><![CDATA[Rocky Brands Inc.]]></category>
		<category><![CDATA[RRR]]></category>
		<category><![CDATA[RSC Holdings Inc.]]></category>
		<category><![CDATA[RVBD]]></category>
		<category><![CDATA[Safe Bulkers Inc.]]></category>
		<category><![CDATA[SanDisk Corporation]]></category>
		<category><![CDATA[Sandy Spring Bancorp Inc]]></category>
		<category><![CDATA[SASR]]></category>
		<category><![CDATA[SB]]></category>
		<category><![CDATA[SBCF]]></category>
		<category><![CDATA[Schlumberger Limited]]></category>
		<category><![CDATA[SCHN]]></category>
		<category><![CDATA[Schnitzer Steel Industries Inc]]></category>
		<category><![CDATA[SCHW]]></category>
		<category><![CDATA[SCL]]></category>
		<category><![CDATA[SCSS]]></category>
		<category><![CDATA[Seacoast Banking Corporation of Florida]]></category>
		<category><![CDATA[Seacor Holdings Inc.]]></category>
		<category><![CDATA[Seagate Technology]]></category>
		<category><![CDATA[SEI Investments Company]]></category>
		<category><![CDATA[SEIC]]></category>
		<category><![CDATA[Select Comfort Corporation]]></category>
		<category><![CDATA[Sensient Technologies Corporation]]></category>
		<category><![CDATA[SFNC]]></category>
		<category><![CDATA[Shaw Communications Inc.]]></category>
		<category><![CDATA[Simmons First National Corporation]]></category>
		<category><![CDATA[SIVB]]></category>
		<category><![CDATA[SJR]]></category>
		<category><![CDATA[SLB]]></category>
		<category><![CDATA[SLM]]></category>
		<category><![CDATA[Slm Corporation]]></category>
		<category><![CDATA[SNA]]></category>
		<category><![CDATA[Snap-on Inc.]]></category>
		<category><![CDATA[SNDK]]></category>
		<category><![CDATA[SON]]></category>
		<category><![CDATA[SONC]]></category>
		<category><![CDATA[Sonic Corporation]]></category>
		<category><![CDATA[Sonoco Products Company]]></category>
		<category><![CDATA[Southwest Airlines Company]]></category>
		<category><![CDATA[Southwest Bancorp Inc]]></category>
		<category><![CDATA[Spartan Stores Inc.]]></category>
		<category><![CDATA[SPTN]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[Stanley Black & Decker]]></category>
		<category><![CDATA[Stanley Furniture Company Inc]]></category>
		<category><![CDATA[State Street Corporation]]></category>
		<category><![CDATA[Steel Dynamics Inc.]]></category>
		<category><![CDATA[Stepan Company]]></category>
		<category><![CDATA[STI]]></category>
		<category><![CDATA[STJ]]></category>
		<category><![CDATA[STLD]]></category>
		<category><![CDATA[STLY]]></category>
		<category><![CDATA[Stryker Corporation]]></category>
		<category><![CDATA[STT]]></category>
		<category><![CDATA[STX]]></category>
		<category><![CDATA[SunTrust Banks Inc.]]></category>
		<category><![CDATA[SUPERVALU Inc.]]></category>
		<category><![CDATA[SVB Financial Group]]></category>
		<category><![CDATA[SVU]]></category>
		<category><![CDATA[SWK]]></category>
		<category><![CDATA[SXT]]></category>
		<category><![CDATA[SY Bancorp Inc.]]></category>
		<category><![CDATA[SYBT]]></category>
		<category><![CDATA[SYK]]></category>
		<category><![CDATA[SYNA]]></category>
		<category><![CDATA[Synaptics Inc]]></category>
		<category><![CDATA[T]]></category>
		<category><![CDATA[Taubman Centers Inc.]]></category>
		<category><![CDATA[TBBK]]></category>
		<category><![CDATA[TCB]]></category>
		<category><![CDATA[TCBI]]></category>
		<category><![CDATA[TCF Financial Corporation]]></category>
		<category><![CDATA[TCO]]></category>
		<category><![CDATA[Temple-Inland Inc.]]></category>
		<category><![CDATA[Tempur Pedic International Inc]]></category>
		<category><![CDATA[TESS]]></category>
		<category><![CDATA[TESSCO Technologies Inc.]]></category>
		<category><![CDATA[Texas Capital BancShares Inc.]]></category>
		<category><![CDATA[Textron Inc.]]></category>
		<category><![CDATA[The Bancorp Inc]]></category>
		<category><![CDATA[The Bank of New York Mellon Corporation]]></category>
		<category><![CDATA[The Blackstone Group]]></category>
		<category><![CDATA[The Cheesecake Factory Incorporated]]></category>
		<category><![CDATA[The Chubb Corporation]]></category>
		<category><![CDATA[The Coca-Cola Company]]></category>
		<category><![CDATA[The McClatchy Company]]></category>
		<category><![CDATA[The McGraw-Hill Companies Inc]]></category>
		<category><![CDATA[The New York Times Company]]></category>
		<category><![CDATA[The Travelers Companies Inc.]]></category>
		<category><![CDATA[Thomas & Betts Corporation]]></category>
		<category><![CDATA[TIN]]></category>
		<category><![CDATA[TNB]]></category>
		<category><![CDATA[TPX]]></category>
		<category><![CDATA[Tractor Supply Company]]></category>
		<category><![CDATA[Travelzoo Inc.]]></category>
		<category><![CDATA[TRIB]]></category>
		<category><![CDATA[Trinity Biotech plc]]></category>
		<category><![CDATA[TRV]]></category>
		<category><![CDATA[TSCO]]></category>
		<category><![CDATA[TXT]]></category>
		<category><![CDATA[TZOO]]></category>
		<category><![CDATA[UAL]]></category>
		<category><![CDATA[UBNK]]></category>
		<category><![CDATA[Ultratech Inc.]]></category>
		<category><![CDATA[UMPQ]]></category>
		<category><![CDATA[Umpqua Holdings Corporation]]></category>
		<category><![CDATA[UNF]]></category>
		<category><![CDATA[UNH]]></category>
		<category><![CDATA[UniFirst Corporation]]></category>
		<category><![CDATA[Union Pacific Corporation]]></category>
		<category><![CDATA[United Continental Holdings]]></category>
		<category><![CDATA[United Financial Bancorp]]></category>
		<category><![CDATA[United Rentals Inc]]></category>
		<category><![CDATA[United Technologies Corporation]]></category>
		<category><![CDATA[Unitedhealth Group Inc.]]></category>
		<category><![CDATA[UNP]]></category>
		<category><![CDATA[URI]]></category>
		<category><![CDATA[US Airways Group Inc.]]></category>
		<category><![CDATA[Us Bancorp]]></category>
		<category><![CDATA[USA Truck Inc.]]></category>
		<category><![CDATA[USAK]]></category>
		<category><![CDATA[USB]]></category>
		<category><![CDATA[USG]]></category>
		<category><![CDATA[USG Corporation]]></category>
		<category><![CDATA[UTEK]]></category>
		<category><![CDATA[UTX]]></category>
		<category><![CDATA[Valley National Bancorp]]></category>
		<category><![CDATA[VCBI]]></category>
		<category><![CDATA[Verizon Communications Inc.]]></category>
		<category><![CDATA[Viad Corporation]]></category>
		<category><![CDATA[Virginia Commerce Bancorp Inc]]></category>
		<category><![CDATA[VLY]]></category>
		<category><![CDATA[VMW]]></category>
		<category><![CDATA[VMware Inc.]]></category>
		<category><![CDATA[VVI]]></category>
		<category><![CDATA[VZ]]></category>
		<category><![CDATA[W.W. Grainger Inc]]></category>
		<category><![CDATA[WABC]]></category>
		<category><![CDATA[WAL]]></category>
		<category><![CDATA[Washington Federal Inc]]></category>
		<category><![CDATA[Waste Connections Inc.]]></category>
		<category><![CDATA[Watsco Inc.]]></category>
		<category><![CDATA[WCC]]></category>
		<category><![CDATA[WCN]]></category>
		<category><![CDATA[WD-40 Company]]></category>
		<category><![CDATA[WDC]]></category>
		<category><![CDATA[WDFC]]></category>
		<category><![CDATA[Wells Fargo & Company]]></category>
		<category><![CDATA[WERN]]></category>
		<category><![CDATA[Werner Enterprises Inc.]]></category>
		<category><![CDATA[WESCO International Inc.]]></category>
		<category><![CDATA[Westamerica BanCorporation]]></category>
		<category><![CDATA[Westell Technologies Inc]]></category>
		<category><![CDATA[Western Alliance Bancorporation]]></category>
		<category><![CDATA[Western Digital Corporation]]></category>
		<category><![CDATA[Westwood Holdings Group Inc]]></category>
		<category><![CDATA[WFC]]></category>
		<category><![CDATA[WFSL]]></category>
		<category><![CDATA[WHG]]></category>
		<category><![CDATA[WNS]]></category>
		<category><![CDATA[WNS (Holdings) Limited]]></category>
		<category><![CDATA[WSO]]></category>
		<category><![CDATA[WSTL]]></category>
		<category><![CDATA[WYNN]]></category>
		<category><![CDATA[Wynn Resorts Limited]]></category>
		<category><![CDATA[Xilinx Inc.]]></category>
		<category><![CDATA[XLNX]]></category>
		<category><![CDATA[XXIA]]></category>
		<category><![CDATA[Yahoo! Inc.]]></category>
		<category><![CDATA[YHOO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=85152</guid>
		<description><![CDATA[Earnings Preview 10/14/11 While the earnings season kicked off this past week, only 38 firms reported. The game really gets under way next week, when we will get reports from 336 firms, including 99 members of the S&#38;P 500. Thus, by the end of the week we will have a very good idea of how the overall season will go. Not only will there be a lot of reports, but many of those we get will be very important ones. The table at the end of this report reads like a who’s who of American industry, including: Apple (AAPL), American Express (AXP), Bank of America (BAC), Citigroup (C), General Electric (GE), Goldman Sachs (GS), IBM (IBM), Intel (INTC) and McDonald’s (MCD). And that&#8217;s just the first half of the alphabet! ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/10/17/aapl-a-busy-week-ahead-earnings-preview/85152/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALNY) Alnylam Pharmaceuticals Announces Pipeline Progress</title>
		<link>http://www.stockbloghub.com/2011/10/06/alny-alnylam-pharmaceuticals-announces-pipeline-progress-at-alnylam/84757</link>
		<comments>http://www.stockbloghub.com/2011/10/06/alny-alnylam-pharmaceuticals-announces-pipeline-progress-at-alnylam/84757#comments</comments>
		<pubDate>Thu, 06 Oct 2011 23:38:53 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[HD]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[The Home Depot Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=84757</guid>
		<description><![CDATA[Recently, Alnylam Pharmaceuticals Inc. (ALNY) announced the commencement of an early-stage stage study (n~32) of its RNAi (RNA (Ribo Nucleic Acid) interference) therapeutic program ALN-PCS for treating patients suffering from hypercholesterolemia. Hypercholesterolemia indicates a situation where the cholesterol levels in the blood are higher than normal. The randomized, single-blind, placebo-controlled, single-ascending dose study intends to evaluate the safety and tolerability of the candidate in patients suffering from high low-density lipoprotein cholesterol (LDLc or “bad” cholesterol). Moreover, the clinical activity of ALN-PCS is also expected to be assessed through the study on the basis of measurements of plasma PCSK9 protein and serum LDLc. Results from the study, which is being conducted in the UK, are expected by year end. ALN-PCS is a part of Alnylam’s core product strategy &#8211; 5&#215;15 introduced ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/10/06/alny-alnylam-pharmaceuticals-announces-pipeline-progress-at-alnylam/84757/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALNY) Alnylam Pharmaceuticals Analyst Maintains Neutral Rating on Shares</title>
		<link>http://www.stockbloghub.com/2011/08/30/alny-alnylam-pharmaceuticals-analyst-maintains-neutral-rating-on-shares/82322</link>
		<comments>http://www.stockbloghub.com/2011/08/30/alny-alnylam-pharmaceuticals-analyst-maintains-neutral-rating-on-shares/82322#comments</comments>
		<pubDate>Tue, 30 Aug 2011 21:15:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=82322</guid>
		<description><![CDATA[We have maintained a Neutral rating on Alnylam Pharmaceuticals, Inc (ALNY) with a target price of $7.00 per share. Alnylam Pharmaceuticals Inc. is a biopharmaceutical company developing novel therapeutics based on a biological breakthrough technology known as RNA (Ribo Nucleic Acid) interference (RNAi). Alnylam is currently utilizing this know-how to build a pipeline of drug candidates for the treatment of a wide array of diseases. Alnylam Pharmaceuticals Inc.’s second quarter 2011 loss of 33 cents per share was narrower than the Zacks Consensus Estimate of a loss of 37 cents per share and the year-ago loss of 35 cents per share. Lower operating expenses led to the narrower loss despite lukewarm revenues in the quarter. Revenues for the reported quarter fell 22.6% from the prior year to $20.6 million. Revenues ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/30/alny-alnylam-pharmaceuticals-analyst-maintains-neutral-rating-on-shares/82322/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MRK) Japanese Approval for Merck Products</title>
		<link>http://www.stockbloghub.com/2011/07/11/mrk-japanese-approval-for-merck-products/78598</link>
		<comments>http://www.stockbloghub.com/2011/07/11/mrk-japanese-approval-for-merck-products/78598#comments</comments>
		<pubDate>Mon, 11 Jul 2011 15:54:46 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78598</guid>
		<description><![CDATA[Merck (MRK) recently announced that it received approval for three products in Japan. The Japanese Ministry of Health, Labour and Welfare (MHLW) approved Gardasil [human papillomavirus quadrivalent (Types 6, 11, 16 and 18) vaccine, recombinant], Zolinza (vorinostat) and Cubicin (daptomycin for injection) for use in Japan. Gardasil gained approval for the prevention of cervical cancer (squamous cell cancer and adenocarcinoma) and their precursor lesions (cervical intraepithelial neoplasm grade 1/2/3 and cervical adenocarcinoma in situ), vulvar intraepithelial neoplasia grade 1/2/3, vaginal intraepithelial neoplasia grade 1/2/3 and genital warts caused by HPV types 6, 11, 16 and 18 in females 9 years of age and older. Meanwhile, Zolinza gained approval for the treatment of cutaneous T-cell lymphomas. Cubicin, an antibacterial agent with activity against methicillin-resistant Staphylococcus aureus (MRSA), gained approval for the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/11/mrk-japanese-approval-for-merck-products/78598/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OPTR) Optimer Pharmaceuticals Analyst Maintains Neutral</title>
		<link>http://www.stockbloghub.com/2011/07/05/optr-optimer-pharmaceuticals-analyst-maintains-neutral/78351</link>
		<comments>http://www.stockbloghub.com/2011/07/05/optr-optimer-pharmaceuticals-analyst-maintains-neutral/78351#comments</comments>
		<pubDate>Wed, 06 Jul 2011 00:16:22 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Optimer Pharmaceuticals Inc]]></category>
		<category><![CDATA[OPTR]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Salix Pharmaceuticals Limited]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SLXP]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78351</guid>
		<description><![CDATA[We have maintained a Neutral rating on Optimer Pharmaceuticals, Inc. (OPTR) with a target price of $12.00 per share. We find the US Food and Drug Administration’s (FDA) approval of Optimer’s first drug, antibiotic Dificid, for the treatment of clostridium difficile-associated diarrhea (CDAD), highly encouraging. CDAD is the most common nosocomial or hospital-acquired diarrhea and is a significant malaise in hospitals and nursing home facilities. Dificid (twice daily tablets) is the first drug to be approved in almost 30 years for the treatment of CDAD. Dificid is the only drug which has shown superiority over ViroPharma’s (VPHM) Vancocin &#8211; the only other FDA approved antibiotic for the treatment of clostridium difficile infection &#8211; in sustaining clinical response for CDAD. The superior recurring benefits of Dificid over Vancocin will be included ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/05/optr-optimer-pharmaceuticals-analyst-maintains-neutral/78351/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALNY) Alnylam Pharmaceuticals Analyst Maintains Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2011/06/23/alny-alnylam-pharmaceuticals-analyst-maintains-neutral-on-shares/77291</link>
		<comments>http://www.stockbloghub.com/2011/06/23/alny-alnylam-pharmaceuticals-analyst-maintains-neutral-on-shares/77291#comments</comments>
		<pubDate>Thu, 23 Jun 2011 19:34:26 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77291</guid>
		<description><![CDATA[We have maintained a Neutral rating on Alnylam Pharmaceuticals Inc. (ALNY) with a target price of $9.50 per share. Alnylam Pharmaceuticals Inc. is a biopharmaceutical company developing novel therapeutics based on a biological breakthrough known as RNA (Ribo Nucleic Acid) interference (RNAi). Alnylam is currently utilizing this technology to build a pipeline of drug candidates for the treatment of a wide array of diseases. Alnylam Pharmaceuticals Inc.’s first quarter loss of 38 cents per share was wider than the Zacks Consensus Estimate of 32 cents per share and also the year-ago loss of 29 cents. Lower revenues and higher research and development expenses led to the greater loss. Revenues for the reported quarter fell 15% from the prior year to $20.9 million but were in line with the Zacks Consensus ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/23/alny-alnylam-pharmaceuticals-analyst-maintains-neutral-on-shares/77291/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(THRX) Theravance Analyst Maintains Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2011/06/14/thrx-theravance-analyst-maintains-neutral-on-shares-2/76322</link>
		<comments>http://www.stockbloghub.com/2011/06/14/thrx-theravance-analyst-maintains-neutral-on-shares-2/76322#comments</comments>
		<pubDate>Wed, 15 Jun 2011 03:24:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HAP]]></category>
		<category><![CDATA[Market Vectors RVE Hard Assets Prod ETF]]></category>
		<category><![CDATA[Neenah Paper Inc.]]></category>
		<category><![CDATA[NP]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Theravance Inc]]></category>
		<category><![CDATA[THRX]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76322</guid>
		<description><![CDATA[We have maintained our Neutral recommendation on Theravance, Inc. (THRX) with a target price of $24.00 per share following the announcement of first quarter 2011 financial results. Theravance’s first quarter 2011 loss per share of 28 cents was in line with the Zacks Consensus Estimate, but narrower than the year-ago loss of 35 cents per share. Revenues at Theravance increased 10% year over year to $6.3 million. An increase in royalty revenues from Vibativ sales in the reported quarter was attributable for both the jump in revenues and the narrower year-over-year loss per share. However, total revenue was below the Zacks Consensus Revenue Estimate of $7 million. Theravance has active collaborations with GlaxoSmithKline (GSK) for the Relovair, LAMA/LABA (also called 719/VI) and MABA programs. The Relovair program holds the biggest ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/14/thrx-theravance-analyst-maintains-neutral-on-shares-2/76322/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(THRX) Theravance Analyst Maintains Neutral Rating on Shares</title>
		<link>http://www.stockbloghub.com/2011/06/14/thrx-theravance-analyst-maintains-neutral-rating-on-shares/76253</link>
		<comments>http://www.stockbloghub.com/2011/06/14/thrx-theravance-analyst-maintains-neutral-rating-on-shares/76253#comments</comments>
		<pubDate>Tue, 14 Jun 2011 15:03:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HAP]]></category>
		<category><![CDATA[Market Vectors RVE Hard Assets Prod ETF]]></category>
		<category><![CDATA[Neenah Paper Inc.]]></category>
		<category><![CDATA[NP]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Theravance Inc]]></category>
		<category><![CDATA[THRX]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76253</guid>
		<description><![CDATA[We have maintained our Neutral recommendation on Theravance, Inc. (THRX) with a target price of $24.00 per share following the announcement of first quarter 2011 financial results. Theravance’s first quarter 2011 loss per share of 28 cents was in line with the Zacks Consensus Estimate, but narrower than the year-ago loss of 35 cents per share. Revenues at Theravance increased 10% year over year to $6.3 million. An increase in royalty revenues from Vibativ sales in the reported quarter was attributable for both the jump in revenues and the narrower year-over-year loss per share. However, total revenue was below the Zacks Consensus Revenue Estimate of $7 million. Theravance has active collaborations with GlaxoSmithKline (GSK) for the Relovair, LAMA/LABA (also called 719/VI) and MABA programs. The Relovair program holds the biggest ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/14/thrx-theravance-analyst-maintains-neutral-rating-on-shares/76253/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OPTR) Optimer Pharma Beats on One-Time Gain</title>
		<link>http://www.stockbloghub.com/2011/05/10/optr-optimer-pharma-beats-on-one-time-gain/73730</link>
		<comments>http://www.stockbloghub.com/2011/05/10/optr-optimer-pharma-beats-on-one-time-gain/73730#comments</comments>
		<pubDate>Wed, 11 May 2011 05:28:09 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[CDI]]></category>
		<category><![CDATA[CDI Corporation]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Optimer Pharmaceuticals Inc]]></category>
		<category><![CDATA[OPTR]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Salix Pharmaceuticals Limited]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SLXP]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73730</guid>
		<description><![CDATA[Optimer Pharma’s (OPTR) first quarter 2011 earnings of $1.14 per share tellingly reversed the year-ago loss of 39 cents per share and exceeded the Zacks Consensus Estimate of 30 cents. The earnings beat was due to a huge increase in the top-line in the reported quarter. In the first quarter, revenues were $69.3 million versus $0.30 million in the prior-year quarter. Optimer does not have any marketed products at present. The substantial year-over-year growth was due to the receipt of a one-time $69.2 million upfront payment from Astellas Pharma in exchange for development and commercialization rights for fidaxomicin in certain territories outside US. Fidaxomicin is Optimer’s primary drug candidate which is currently under review both in the US and Europe for the treatment of Clostridium difficile infection (CDI). Fidaxomicin will ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/10/optr-optimer-pharma-beats-on-one-time-gain/73730/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OPTR) Optimer Pharmaceuticals Partners With Cubist Pharmaceuticals for Dificid</title>
		<link>http://www.stockbloghub.com/2011/04/07/optr-optimer-pharmaceuticals-partners-with-cubist-pharmaceuticals-for-dificid/70927</link>
		<comments>http://www.stockbloghub.com/2011/04/07/optr-optimer-pharmaceuticals-partners-with-cubist-pharmaceuticals-for-dificid/70927#comments</comments>
		<pubDate>Thu, 07 Apr 2011 17:24:13 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[CDI]]></category>
		<category><![CDATA[CDI Corporation]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Optimer Pharmaceuticals Inc]]></category>
		<category><![CDATA[OPTR]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Salix Pharmaceuticals Limited]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SLXP]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=70927</guid>
		<description><![CDATA[Optimer Pharmaceuticals Inc. (OPTR) recently announced an exclusive two-year agreement with Cubist Pharmaceuticals Inc. (CBST) to co-promote its lead pipeline candidate, fidaxomicin, to be sold as Dificid in the US. The collaboration follows on the heels of a US panel backing for Dificid for the treatment of Clostridium difficile infection (CDI), which is also known as Clostridium difficile-associated diarrhea (CDAD). The FDA decision on Dificid is expected in May 2011. The candidate is also under regulatory review in the EU. Per the terms of the deal, Optimer will book sales on the candidate, if approved. Optimer also retains the new drug application (NDA) for Dificid. It will also be responsible for FDA approval and manufacturing of the candidate. In exchange for its efforts in co-promoting Dificid, Cubist will be entitled ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/07/optr-optimer-pharmaceuticals-partners-with-cubist-pharmaceuticals-for-dificid/70927/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ADI) Company News for April 06, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/04/06/adi-company-news-for-april-06-2011-corporate-summary/70798</link>
		<comments>http://www.stockbloghub.com/2011/04/06/adi-company-news-for-april-06-2011-corporate-summary/70798#comments</comments>
		<pubDate>Wed, 06 Apr 2011 18:38:00 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Semiconductor - Broad Line]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Abercrombie & Fitch Company]]></category>
		<category><![CDATA[ADI]]></category>
		<category><![CDATA[AMR]]></category>
		<category><![CDATA[AMR Corporation]]></category>
		<category><![CDATA[Analog Devices Inc.]]></category>
		<category><![CDATA[ANF]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[DGW]]></category>
		<category><![CDATA[Diamond Foods Inc.]]></category>
		<category><![CDATA[DMND]]></category>
		<category><![CDATA[DUOYUAN GLOBAL WATER]]></category>
		<category><![CDATA[EXPE]]></category>
		<category><![CDATA[Expedia Inc.]]></category>
		<category><![CDATA[PG]]></category>
		<category><![CDATA[Procter & Gamble Company]]></category>
		<category><![CDATA[The TJX Companies Inc.]]></category>
		<category><![CDATA[TJX]]></category>
		<category><![CDATA[TM]]></category>
		<category><![CDATA[Toyota Motor Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=70798</guid>
		<description><![CDATA[• Expedia, Inc. (NASDAQ:EXPE) and American Airlines (NYSE:AMR) have reached an agreement regarding fees and how travel information should be delivered on its website • Abercrombie &#38; Fitch Co. (NYSE:ANF) rocketed 10.82% to close at $65.57 after the company hosted its first analyst day in several years • Wedbush analysts upgraded Cubist Pharmaceuticals, Inc. (NASDAQ:CBST) from &#8220;Neutral&#8221; to &#8220;Outperform&#8221; rating • Shares prices of snack-food maker Diamond Foods Inc. (NASDAQ:DMND) increased 6.71% after the company unveiled plans to acquire the Pringles chips business from Procter &#38; Gamble Co. (NYSE:PG) • According to a report,  Duoyuan Global Water Inc.’s (NYSE:DGW) Chief Financial Officer Stephen Park is resigning from the firm • Share prices of The TJX Companies, Inc. (NYSE:TJX) increased 2.76% after the board approved a 27% dividend increase • Toyota Motor Corporation (NYSE:TM) plans to close down ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/06/adi-company-news-for-april-06-2011-corporate-summary/70798/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(THRX) Theravance Analyst Maintains Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2011/04/02/thrx-theravance-analyst-maintains-neutral-on-shares/70204</link>
		<comments>http://www.stockbloghub.com/2011/04/02/thrx-theravance-analyst-maintains-neutral-on-shares/70204#comments</comments>
		<pubDate>Sat, 02 Apr 2011 15:18:09 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Theravance Inc]]></category>
		<category><![CDATA[THRX]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=70204</guid>
		<description><![CDATA[We are maintaining our Neutral recommendation on Theravance, Inc. (THRX) with a target price of $25.00 after the company&#8217;s fourth quarter and fiscal year 2010 financial results. Theravance’s fourth quarter 2010 loss per share of 25 cents was narrower than both the Zacks Consensus Estimate for a loss of 28 cents and the year-ago loss of 35 cents per share. The earnings improvement was driven by a better top-line performance and lower research and development costs. Revenue at Theravance increased more than 80% over the prior year to $6.9 million. Revenue was also slightly above the Zacks Consensus Revenue Estimate of $6 million. Theravance has active collaborations with GlaxoSmithKline (GSK) for the Relovair, LAMA/LABA (also called 719/VI) and MABA programs. The Relovair program holds the biggest potential in the company’s pipeline, which ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/02/thrx-theravance-analyst-maintains-neutral-on-shares/70204/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALNY) Alnylam Pharmaceuticals Reports Smaller Third Quarter Loss Than Expected</title>
		<link>http://www.stockbloghub.com/2010/11/25/alny-alnylam-pharmaceuticals-reports-smaller-third-quarter-loss-than-expected/58805</link>
		<comments>http://www.stockbloghub.com/2010/11/25/alny-alnylam-pharmaceuticals-reports-smaller-third-quarter-loss-than-expected/58805#comments</comments>
		<pubDate>Fri, 26 Nov 2010 04:33:24 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=58805</guid>
		<description><![CDATA[Alnylam Pharmaceuticals Inc.’s (ALNY) third quarter loss of 23 cents per share was narrower than the Zacks Consensus Estimate of 39 cents but wider than the year-ago loss of 22 cents per share. The wider loss in the third quarter of 2010 was primarily attributable to the higher spend on research and development during the quarter. Revenues for the reported quarter climbed 14% to $27.7 million, above the Zacks Consensus Estimate of $26 million. Revenues were inclusive of $14 million from the company’s alliance with Roche (RHHBY), $5.6 million from Alnylam‘s partnership with Takeda Pharmaceuticals, in addition to $8.1 million of expense reimbursement and amortization revenues from Novartis (NVS), the National Institutes of Health, Cubist Pharmaceuticals Inc. (CBST) and Biogen Idec Inc. (BIIB) among others. Research and development (R&#38;D) costs ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/25/alny-alnylam-pharmaceuticals-reports-smaller-third-quarter-loss-than-expected/58805/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALNY) Alnylam Pharmaceuticals Analyst Awards Neutral Rating</title>
		<link>http://www.stockbloghub.com/2010/09/09/alny-alnylam-pharmaceuticals-analyst-awards-neutral-rating/50978</link>
		<comments>http://www.stockbloghub.com/2010/09/09/alny-alnylam-pharmaceuticals-analyst-awards-neutral-rating/50978#comments</comments>
		<pubDate>Fri, 10 Sep 2010 06:05:10 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[CF]]></category>
		<category><![CDATA[CF Industries Holdings]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=50978</guid>
		<description><![CDATA[We are maintaining our Neutral recommendation on Alnylam Pharmaceuticals (ALNY) with a target price of $15. Alnylam, founded in 2002 and headquartered in Cambridge, Massachusetts, focuses on developing novel therapeutics based on a biological breakthrough known as RNA (Ribo Nucleic Acid) interference (RNAi). Alnylam’s founders pioneered the discovery of RNAi, and the company is currently utilizing this technology to build a pipeline of drug candidates for the treatment of a wide array of diseases. Key programs in the areas of respiratory syncytial virus (RSV), Parkinson’s disease (PD), cystic fibrosis (CF) and spinal cord injury round out the company’s core focus. Alnylam generates revenues from research collaborations, grants and licensing of the RNAi technology outside its core focus area. Alnylam has partnerships with several large pharmaceutical companies, such as Novartis (NVS), ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/09/09/alny-alnylam-pharmaceuticals-analyst-awards-neutral-rating/50978/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALNY) Alnylam Pharmaceuticals&#8217; Second Quarter Loss Down on Lower Costs</title>
		<link>http://www.stockbloghub.com/2010/08/05/alny-alnylam-pharmaceuticals-second-quarter-loss-down-on-lower-costs/46791</link>
		<comments>http://www.stockbloghub.com/2010/08/05/alny-alnylam-pharmaceuticals-second-quarter-loss-down-on-lower-costs/46791#comments</comments>
		<pubDate>Thu, 05 Aug 2010 17:22:09 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=46791</guid>
		<description><![CDATA[Alnylam Pharmaceuticals Inc.’s (ALNY) second-quarter net loss of 35 cents per share was 20 cents below the loss per share in the second quarter of 2009. The Zacks Consensus Estimate indicated a loss of 30 cents per share for the reported quarter. The narrower year-over-year loss in the second quarter of 2010 was primarily attributable to the lower spend on research and development during the quarter. Revenues for the reported quarter climbed 8% to $26.6 million slightly above the Zacks Consensus Revenue Estimate of $26 million. Revenues were inclusive of $14 million from the company’s alliance with Roche HLDG LTD(RHHBY), $5.5 million from Alnylam‘s partnership with Takeda Pharmaceuticals, $1.9 million in revenues from license fee from Regulus Therapeutics Inc. pertaining to the partnership with Sanofi-Aventis (SNY), in addition to $5.2 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/05/alny-alnylam-pharmaceuticals-second-quarter-loss-down-on-lower-costs/46791/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CBST) Cubist Pharmaceuticals Earns Some Attention</title>
		<link>http://www.stockbloghub.com/2010/05/09/cbst-cubist-pharmaceuticals-earns-some-attention/36659</link>
		<comments>http://www.stockbloghub.com/2010/05/09/cbst-cubist-pharmaceuticals-earns-some-attention/36659#comments</comments>
		<pubDate>Mon, 10 May 2010 05:20:30 +0000</pubDate>
		<dc:creator>Wax</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Oncothyreon Inc]]></category>
		<category><![CDATA[ONTY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=36659</guid>
		<description><![CDATA[We were asked last week why we never investigated biotechnology companies. To set the record straight, we own shares in a biotechnology company, Oncothyreon, Inc. (NASDAQ: ONTY), a clinical stage company developing cancer treatment therapies. But to answer the question directly, we don&#8217;t investigate biotechnology companies because the vast majority offer little in the way investment risk mitigation, which is a polite way of saying that an investment in companies in the biotechnology sector is a very big gamble, and if we wanted to gamble we would just go to Las Vegas where we think there a better odds. Enter Cubist Pharmaceuticals, Inc. (NASDAQ: CBST), a company focusing on acute care. It was the &#8220;acute care&#8221; part that piqued our curiosity. Basis Financial information related to Cubist Pharmaceuticals, Inc. contained ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/09/cbst-cubist-pharmaceuticals-earns-some-attention/36659/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CBST) Cubist Pharmaceuticals Misses Expectations &#8211; Revenues Move Up</title>
		<link>http://www.stockbloghub.com/2010/04/18/cbst-cubist-pharmaceuticals-misses-expectations-revenues-move-up/34108</link>
		<comments>http://www.stockbloghub.com/2010/04/18/cbst-cubist-pharmaceuticals-misses-expectations-revenues-move-up/34108#comments</comments>
		<pubDate>Mon, 19 Apr 2010 02:58:26 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=34108</guid>
		<description><![CDATA[Cubist Pharmaceuticals (CBST) reported earnings per share of 34 cents for the first quarter of 2010 compared to 13 cents in the year-ago period. Last year’s quarter included a $20 million charge related to the upfront payment made under an exclusive agreement to Alnylam Pharmaceuticals (ALNY). The Zacks Consensus Estimate for the quarter was 35 cents. However, after treating stock-based compensation as a regular expense and excluding non-recurring items, EPS for the quarter was 43 cents, higher than 37 cents in the year-ago period. Revenue for the quarter recorded a year over year increase of 19% to $144.1 million. The primary reason for increased revenue was higher sales of Cubicin (daptomycin for injection) in the domestic market &#8211; $135.3 million (year-over-year growth of 20%). Sales in the international market increased ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/18/cbst-cubist-pharmaceuticals-misses-expectations-revenues-move-up/34108/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CBST) Cubist Pharmaceuticals Initiates Mid-stage Trial</title>
		<link>http://www.stockbloghub.com/2010/04/14/cbst-cubist-pharmaceuticals-initiates-mid-stage-trial/33714</link>
		<comments>http://www.stockbloghub.com/2010/04/14/cbst-cubist-pharmaceuticals-initiates-mid-stage-trial/33714#comments</comments>
		<pubDate>Wed, 14 Apr 2010 21:51:02 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=33714</guid>
		<description><![CDATA[Recently, Cubist Pharmaceuticals (CBST) began a mid-stage trial of one of its pipeline candidates, CB-183,315. The drug is being studied to treat patients suffering from diarrhea caused by Clostridium difficile also known as C. difficile-associated diarrhea or CDAD. The phase II trial is likely to enroll over 200 patients at multiple locations in the U.S and Canada. The trial is designed to evaluate the safety and effectiveness of CB-183,315 compared to Vancocin. CB-183,315 will be studied in two dosage forms – 125 mg twice daily and 250 mg twice daily compared to Vancocin in a 125 mg dose to be administered four times a day for over a period of 10 days. While we are pleased with the development in the company’s pipeline, we remain concerned about the outcome of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/14/cbst-cubist-pharmaceuticals-initiates-mid-stage-trial/33714/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CBST) Cubist Pharmaceuticals Ends Drug Trial</title>
		<link>http://www.stockbloghub.com/2010/04/01/cbst-cubist-pharmaceuticals-ends-drug-trial/32587</link>
		<comments>http://www.stockbloghub.com/2010/04/01/cbst-cubist-pharmaceuticals-ends-drug-trial/32587#comments</comments>
		<pubDate>Thu, 01 Apr 2010 16:23:18 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[DYAX]]></category>
		<category><![CDATA[Dyax Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=32587</guid>
		<description><![CDATA[Cubist Pharmaceuticals Inc. (CBST) has stopped a mid-stage trial of one of its pipeline candidates, CB-500,929 (ecallantide). The drug was being studied for lowering blood loss in patients undergoing cardiac surgery using cardiopulmonary bypass (CPB). The decision to stop the trial was taken following a review of safety and efficacy data from two phase II trials – CONSERV 1 and CONSERV 2. However, this does not impact the 2010 R&#38;D cost guidance as it did not include the cost of development of ecallantide beyond the CONSERV trials. The CONSERV 1 trial was conducted on 249 patients undergoing Coronary Artery Bypass Graft (CABG) Surgery using CPB. No improvement in blood loss was observed in patients who were administered CB-500,929 in three dosages of 5, 25 or 75 mg compared to placebo. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/01/cbst-cubist-pharmaceuticals-ends-drug-trial/32587/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CBST) Cubist Pharmaceuticals Misses Estimates</title>
		<link>http://www.stockbloghub.com/2010/01/23/cbst-cubist-pharmaceuticals-misses-estimates/25750</link>
		<comments>http://www.stockbloghub.com/2010/01/23/cbst-cubist-pharmaceuticals-misses-estimates/25750#comments</comments>
		<pubDate>Sat, 23 Jan 2010 21:15:07 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=25750</guid>
		<description><![CDATA[Cubist Pharmaceuticals (CBST) reported earnings per share (EPS) of 38 cents for the fourth quarter of 2009, missing the Zacks Consensus Estimate by 3 cents and down from $1.43 reported in the year-ago period. Last year’s results were inflated by a tax benefit of $100 million. However, excluding non-recurring expenses and income, EPS for the fourth quarter was 68 cents, a marginal decline compared to 71 cents reported in the year-ago period. For the full year, Cubist reported EPS of $2.29, an increase of 26% compared to the year-ago period. Revenues for the quarter ($167 million) as well as the full year ($562 million) recorded a year-over-year increase of 27% and 30%, respectively. The primary reason for increased revenues was higher sales of Cubicin (daptomycin for injection) in the U.S. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/23/cbst-cubist-pharmaceuticals-misses-estimates/25750/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Johnson and Johnson Suffers Another Pipeline Setback</title>
		<link>http://www.stockbloghub.com/2009/12/31/jnj-johnson-and-johnson-suffers-another-pipeline-setback/24014</link>
		<comments>http://www.stockbloghub.com/2009/12/31/jnj-johnson-and-johnson-suffers-another-pipeline-setback/24014#comments</comments>
		<pubDate>Thu, 31 Dec 2009 18:24:34 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Theravance Inc]]></category>
		<category><![CDATA[THRX]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=24014</guid>
		<description><![CDATA[Johnson and Johnson (JNJ) has received yet another setback related to its pipeline candidate ceftobiprole, a broad-spectrum antibiotic ? aiming the methicillin-resistant Staphylococcus aureus (MRSA) ? for the treatment of complicated skin infections and nosocomial pneumonia. Johnson and Johnson had licensed the drug from Swiss drug company Basilea Pharmaceuticals in 2005. Johnson and Johnson received a complete response letter (CRL) from the US Food and Drug Administration (FDA), delaying the approval process further. According to the FDA, there were many flaws in the trials due to which the company has been asked to conduct new studies to evaluate the drug&#8217;s safety and effectiveness. Johnson and Johnson intends to discuss its future course of action related to ceftobiprole with the FDA shortly. The new drug application (NDA) for ceftobiprole has been ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/31/jnj-johnson-and-johnson-suffers-another-pipeline-setback/24014/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CBST) Cubist to Aquire Calixa Therapeutics</title>
		<link>http://www.stockbloghub.com/2009/12/16/cbst-cubist-to-aquire-calixa-therapeutics/23005</link>
		<comments>http://www.stockbloghub.com/2009/12/16/cbst-cubist-to-aquire-calixa-therapeutics/23005#comments</comments>
		<pubDate>Wed, 16 Dec 2009 22:43:56 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[DYAX]]></category>
		<category><![CDATA[Dyax Corporation]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=23005</guid>
		<description><![CDATA[Recently, Cubist Pharmaceuticals (CBST) decided to acquire a privately held biopharmaceutical company Calixa Therapeutics for an upfront payment of $92.5 million. Additionally, Cubist would be required to make a payment of another $310 million on the achievement of certain development, regulatory, and commercial milestones. Calixa is primarily focused on the development of antibiotics to treat serious bacterial infections. The deal is expected to close by year end. Following the deal, Cubist will gain rights to Calixa’s lead compound CXA-201 (containing CXA-101), an intravenous treatment in mid-stage trial for the treatment of urinary tract and intra-abdominal infections caused by Pseudomonas aeruginosa. In addition, Cubist will also receive rights to another compound CXA-101 and any other drugs incorporating CXA-101, which was acquired from Astellas Pharma. Cubist plans to begin clinical studies of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/16/cbst-cubist-to-aquire-calixa-therapeutics/23005/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CBST) Cubist Pharmaceuticals Beats Earnings Estimates</title>
		<link>http://www.stockbloghub.com/2009/10/16/cbst-cubist-pharmaceuticals-beats-earnings-estimates/17874</link>
		<comments>http://www.stockbloghub.com/2009/10/16/cbst-cubist-pharmaceuticals-beats-earnings-estimates/17874#comments</comments>
		<pubDate>Fri, 16 Oct 2009 23:59:14 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=17874</guid>
		<description><![CDATA[Cubist Pharmaceuticals, Inc. (CBST) reported a third-quarter net income of 65 cents per share, which was much higher than the Zacks Consensus Estimate of 33 cents. The company’s net income was 48 cents per share in the year-ago quarter. The higher profit in the quarter was primarily because of increased sales coming from all the segments. Revenues in the quarter increased 28% to $143.5 million. U.S. product revenues increased 26.1% to $137.66 million in the quarter. Cubist recorded international product revenues of $3.93 million as against $1.43 million last year. Service revenues came in at $1.50 million from $1.42 million, and other revenues increased to $0.45 million from $0.39 million. Research &#38; Development (R&#38;D) spend for the quarter increased 24.1% to $35.5 million. Sales &#38; Marketing expenses for the quarter ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/16/cbst-cubist-pharmaceuticals-beats-earnings-estimates/17874/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(THRX) Theravance Earns FDA Approval for Skin Infection Drug</title>
		<link>http://www.stockbloghub.com/2009/09/16/thrx-theravance-earns-fda-approval-for-skin-infection-drug/15265</link>
		<comments>http://www.stockbloghub.com/2009/09/16/thrx-theravance-earns-fda-approval-for-skin-infection-drug/15265#comments</comments>
		<pubDate>Wed, 16 Sep 2009 16:22:12 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Theravance Inc]]></category>
		<category><![CDATA[THRX]]></category>
		<category><![CDATA[Viropharma Incorporated]]></category>
		<category><![CDATA[VPHM]]></category>
		<category><![CDATA[WYE]]></category>
		<category><![CDATA[Wyeth]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=15265</guid>
		<description><![CDATA[In a quantum achievement, Theravance (THRX) received approval from the US Food and Drug Administration (FDA) to market its Vibativ (telavancin) for complicated skin and skin structure infections (cSSSI) caused by Gram-positive bacteria. Vibativ, jointly developed with Japan’s Astellas Pharma, is expected to hit the US market by end of this year. While the drug will be marketed and sold by Astellas, Theravance will receive royalties on global sales. In the U.S., the company will help Astellas in marketing the drug for the first three years post approval. Apart from cSSSI, Vibativ is also being studied for hospital-acquired pneumonia (HAP). The company has already submitted a New Drug Application (NDA) for this indication and has been assigned a Prescription Drug User Fee Act (PDUFA) date of Nov. 26. The approval ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/16/thrx-theravance-earns-fda-approval-for-skin-infection-drug/15265/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
